

Edgar Filing: DIACRIN INC /DE/ - Form 10-K

DIACRIN INC /DE/
Form 10-K
March 28, 2002

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 10-K
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2001

Commission File No. 0-20139

Diacrin, Inc.
(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of
incorporation or organization)

22-3016912
(I.R.S. Employer
Identification No.)

Building 96 13th Street, Charlestown Navy
Yard, Charlestown, MA 02129
(Address of principal executive offices,
including zip code)

(617) 242-9100
(Registrant's telephone number, including area code)

Securities registered pursuant to Section 12 (b) of the Act:

Title of each class	Name of each exchange on which registered
None	None

Securities registered pursuant to Section 12 (g) of the Act:

Title of each class
Common Stock, \$.01 par value

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. YES X NO .

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. []

The approximate aggregate market value of the voting stock held by non-affiliates of the registrant (based on the closing price of the Common Stock on March 15, 2002) was \$22,056,383.

As of March 15, 2002, 17,937,204 shares of the registrant's Common Stock were outstanding.

Edgar Filing: DIACRIN INC /DE/ - Form 10-K

Cautionary Note Regarding Forward-Looking Statements

This Annual Report on Form 10-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 concerning our business, operations and financial condition, including statements with respect to planned timetables for the initiation and completion of various clinical trials, development funding expected to be received in connection with our joint venture and the expected sources of porcine cells used in our products. All statements, other than statements of historical facts included in this Annual Report on Form 10-K regarding our strategy, future operations, timetables for product testing, financial position, costs, prospects, plans and objectives of management are forward-looking statements. When used in this Annual Report on Form 10-K, the words "expect," "anticipate," "intend," "plan," "believe," "seek," "estimate" and similar expressions are intended to identify forward looking statements, although not all forward-looking statements contain these identifying words. Because these forward-looking statements involve risks and uncertainties, actual results could differ materially from those expressed or implied by these forward-looking statements for a number of important reasons, including those discussed under "Certain Factors That May Affect Future Results," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in this Annual Report on Form 10-K.

You should read these statements carefully because they discuss our expectations about our future performance, contain projections of our future operating results or our future financial condition, or state other "forward-looking" information. You should be aware that the occurrence of any of the events described in these risk factors and elsewhere in this Annual Report on Form 10-K could substantially harm our business, results of operations and financial condition and that upon the occurrence of any of these events, the trading price of our common stock could decline.

We cannot guarantee any future results, levels of activity, performance or achievements. The forward-looking statements contained in this Annual Report on Form 10-K represent our expectations as of the date this Annual Report on Form 10-K was first filed with the Securities and Exchange Commission and should not be relied upon as representing our expectation as of any other date. Subsequent events and developments will cause our expectations to change. However, while we may elect to update these forward-looking statements, we specifically disclaim any obligation to do so even if our expectations change.

PART I

Item 1. Business

Overview

We are developing cell transplantation technology for treating human diseases that are characterized by cell dysfunction or cell death and for which current therapies are either inadequate or nonexistent. Our products under development include:

- Porcine spinal cord cells for spinal cord injury
- Porcine neural cells for stroke

Edgar Filing: DIACRIN INC /DE/ - Form 10-K

- Porcine neural cells for focal epilepsy
- Porcine neural cells for chronic intractable pain
- NeuroCell-PD for Parkinson's disease
- Human liver cells for cirrhosis
- Porcine liver cells for acute liver failure
- Human muscle cells for cardiac disease

Although scientists have demonstrated the feasibility of cell transplantation, an inadequate supply of human donor cells has hampered widespread use of cell transplantation in clinical applications. To overcome this constraint, we have pioneered the use of porcine (pig) cells for clinical transplantation. Because porcine cells are functionally similar to human cells, we believe that pigs will be a reliable source of a wide range of cell types suitable for transplantation into humans. We have shown in preclinical studies and clinical trials that transplanted porcine cells appear capable of integrating into the surrounding tissue and addressing the functional deficits caused by cell damage or cell death.

After receiving clearance from the United States Food and Drug Administration, commonly referred to as the FDA, to conduct the first ever clinical trial of transplanted porcine neural cells in humans, we completed a three-year, twelve-patient, Phase 1 clinical trial to evaluate NeuroCell-PD for the treatment of Parkinson's disease in 1999. Based on encouraging results from this Phase 1 clinical trial, we initiated an 18-patient, pivotal, randomized, double-blinded, placebo-controlled Phase 2 clinical trial of NeuroCell-PD in 1998. In March 2001, the trial was unblinded and we announced a preliminary analysis of the results. We did not see a statistically significant difference between the treated patients and the patients in the control group and, therefore, did not meet the primary endpoint in the trial. Development of NeuroCell-PD is currently suspended while we gather and evaluate additional data.

We are currently evaluating six other product candidates in Phase 1 clinical trials. These include porcine spinal cord cells for spinal cord injury, fetal porcine neural cells for stroke recovery, fetal porcine neural cells for the treatment of focal epilepsy, human liver cells for cirrhosis, porcine liver cells for acute liver failure, and human muscle cells for cardiac disease. We have also received FDA clearance to initiate a Phase 1 clinical trial to evaluate fetal porcine neural cells for chronic intractable pain.

We are also developing a proprietary technology designed to modulate the human immune system in order to prevent rejection of transplanted cells without the use of immunosuppressive drugs. This technology, which we refer to as our immunomodulation technology, involves the selective treatment of cell populations prior to transplantation to prevent the patient's immune system from rejecting the transplanted cells. Our approach would eliminate the need for long-term immunosuppressive drugs, which may leave the patient vulnerable to a wide range of undesirable side effects, including increasing the patient's susceptibility to infections and cancer. We have shown in preclinical and clinical studies the ability of our immunomodulation technology to prevent rejection of transplanted porcine cells without compromising the immune system or causing undesirable side effects. We published scientific evidence in *The Journal of Immunology* in June 1999 that describes how this technology might work to allow survival of transplanted cells.

We were incorporated in October 1989. Our principal executive offices are located at Building 96, 13th Street, Charlestown Navy Yard, Charlestown, MA 02129, and our telephone number at that location is (617) 242-9100.

Diacrin is our trademark. All other trademarks and service marks used in this Annual Report are the property of their respective owners.

Diacrin's Transplantation Technology

We have pioneered the use of fetal porcine cells for clinical transplantation for the treatment of human disease. In March 1995, we received the first FDA clearance to transplant porcine cells into humans. We have developed critical technology relating to the production process for obtaining and screening porcine cells. We are also developing technology to modulate the human immune system to enable porcine cell transplantation into the body without the use of immunosuppressive drugs.

Each step of our production process has been designed based on FDA guidelines and is controlled in order to obtain cells suitable for human transplantation. We have developed procedures to screen pigs for infectious agents and then quarantine qualified donor pigs at our biomedical animal facilities. We harvest cells of appropriate age and type under current good manufacturing procedures, commonly referred to as cGMP, at our facility in Charlestown, Massachusetts.

We perform our screening procedures in accordance with FDA guidelines covering xenotransplantation. These guidelines have been designed to prevent contamination of transplanted cellular products with infectious agents that have the potential to affect human cells. The FDA requires all sponsors of human clinical trials involving porcine tissue, including us, to test for the presence of porcine endogenous retroviruses, commonly known as PERV, in patient blood samples. To date, none of our patients have shown any sign of PERV.

Current transplantation technology generally requires that the patient's immune system be suppressed in order to avoid rejection of transplanted cells. T cells, the main cells involved in directing the body's immune response, recognize and bind to cell surface proteins known as MHC class I proteins. When T cells recognize foreign MHC class I proteins, a cascade of events is triggered which ultimately results in destruction of the transplanted cells that display these foreign proteins. Cyclosporine, a standard immunosuppressive drug, prevents this rejection process. Using cyclosporine, we have demonstrated survival of transplanted porcine cells in a variety of preclinical animal models and have histologically documented survival of transplanted porcine fetal neural cells in a deceased patient who had received NeuroCell-PD.

We are also developing proprietary technology to modulate the immune system to avoid rejection of transplanted cells. We treat isolated cell populations prior to transplantation with antibody fragments directed against MHC class I proteins. This technology is designed to eliminate the need for long-term immunosuppressive drugs. To date the use of our immunomodulation technology in clinical trials has not resulted in any undesirable side effects. Our scientists and academic collaborators have performed preclinical studies which show that cells that have been pretreated using our immunomodulation technology prior to transplantation survived in several animal models without immunosuppression. The long-term survival of the transplanted cells seen in these studies suggests that the recipient's immune system has "learned" to accept the transplant. Thus, we believe that treatment of cells with antibody fragments prior to transplantation will induce a state of graft-specific immunological tolerance, which would allow continued survival of the transplanted cells.

In connection with Phase 1 clinical trials, six Parkinson's disease patients, six Huntington's disease patients, three focal epilepsy patients, five stroke patients and five spinal cord injury patients have been transplanted with antibody-pretreated porcine neural cells, using no immunosuppressive drugs.

Edgar Filing: DIACRIN INC /DE/ - Form 10-K

Preliminary indications from the Phase 1 NeuroCell-PD clinical trial suggest that the improvement in Parkinson's disease symptoms that has occurred in patients transplanted with antibody-treated NeuroCell-PD is comparable to the improvement shown in patients transplanted with NeuroCell-PD with immunosuppressive drugs.

Product Development Programs

We are developing products to address human diseases characterized by cell dysfunction or cell death which represent a broad-based application of our technologies for cell production and transplantation. Our research and development expenses were \$6.4 million, \$6.0 million and \$5.9 million for the years ended December 31, 2001, 2000 and 1999, respectively. The following table summarizes our product development programs in cell transplantation and each product's stage of development:

Diacrin Product Development Programs			
Product Candidate	Disease Indication	U.S. Targeted Patient Population	Status
Porcine spinal cord cells	Spinal cord injury	200,000	Phase 1
Porcine neural cells	Stroke	3,100,000	Phase 1
Porcine neural cells	Focal epilepsy	200,000	Phase 1
Porcine neural cells	Chronic intractable pain	2,100,000	IND cleared
NeuroCell-PD	Parkinson's disease	130,000	Phase 2 (development suspended)
Human liver cells	Cirrhosis	1,100,000	Phase 1
Porcine liver cells	Acute liver failure	45,000	Phase 1
Human muscle cells	Cardiac disease	200,000	Phase 1

Porcine Spinal Cord Cells for Spinal Cord Injury

The prevalence of spinal cord injury, commonly known as SCI, in the United States is approximately 200,000, with 13,000 additional SCIs annually. Nearly 80% of the injured patients are males in their late 20s to early 30s. Greater than 95% of these SCIs are compression injuries, the remainder are cases in which the cord is severed. The spinal cord in the neck is vulnerable to injury because of its extreme mobility, and approximately 80% of SCIs occur in this region. Loss of sensorimotor neuron function due to injury requires lengthy hospitalization after the initial incident as well as extensive rehabilitative care. Furthermore, all victims of SCI face a lifelong series of acute and chronic non-neurological complications that can be life-threatening.

The primary objective of current therapies available for SCIs is to prevent further injury by physically stabilizing the spine and by inhibiting the inflammatory response that results from the injury. These strategies attempt to establish optimal conditions for functional recovery and improve patients' rehabilitative potential. Surgery is designed to protect the patient from further injury through immobilization, spinal cord realignment and stabilization, and decompression. To date, there is no drug therapy available for SCIs except palliative therapies using the corticosteroid,

Edgar Filing: DIACRIN INC /DE/ - Form 10-K

methylprednisolone, to reduce inflammation of the injured area, and standard medical practice for complications arising from chronic denervation.

We believe that the transplantation of porcine fetal spinal cord cells into the site of injury of a damaged human spinal cord may partially reestablish neural pathways. The transplantation of these cells into a recently injured cord may prevent secondary neural and muscular atrophy known to occur in these patients. Partial or full recovery of limb movement, and other motor neural pathways may reduce the overall time spent in the hospital, decrease the secondary equipment required for care, and reduce severe and life threatening complications arising from the injury.

We have initiated a six-patient, Phase 1 clinical trial at Albany Medical Center in Albany, New York and at Washington University Medical Center in St. Louis. As of March 15, 2002, we had treated five patients in this trial. We hope to determine from this trial whether porcine fetal spinal cord cells transplanted into the damaged spinal cord region will engraft and repair the damage, leading to improved mobility and function.

Porcine Neural Cells for Stroke

Stroke is the third leading cause of death in the United States, ranking behind coronary artery disease and cancer. It is also the leading cause of long-term disability in the United States. Approximately 600,000 people suffer a stroke each year and there are 4.4 million people that have been disabled by stroke in the United States. A stroke occurs when the blood supply to a part of the brain is suddenly interrupted. When blood flow to the brain is interrupted, some brain cells die immediately, while others will die days or weeks after the stroke. The death of these brain cells creates a void which becomes a fluid filled cavity in the brain.

Current therapies for stroke target the early events that occur at the time of the stroke. Timely intervention with surgery or with non-invasive therapies that restore blood flow can limit the cell death that occurs. Therapies include surgical intervention to remove a clearly defined clot or anticoagulant therapy to "break up" the clot formation. All current therapies are most effective when administered as quickly as possible after the stroke, and there is a time post-stroke (12-24 hours) after which therapeutic intervention is useless in limiting brain cell death.

Our approach of using porcine fetal neural cell transplantation is based on the premise that many patients who have survived but not fully recovered from a stroke may benefit from the introduction of cells that may repair or replace the damaged neural circuitry. We and others have demonstrated in numerous animal studies the feasibility of repairing and restoring function to a stroke-damaged brain. In an animal model of stroke, we have shown that transplanted porcine fetal neural cells survive at high frequency. These cells not only survived in the brain cavity, but formed solid grafts that integrated appropriately with the normal brain tissue surrounding the cavity. We have observed extensive neural outgrowth from the graft to the surrounding brain and behavioral improvements in a rat model of stroke after transplantation of porcine fetal neural cells. The transplanted cells have the capacity to form billions of new synaptic connections as well as to release other chemicals that promote neural cell growth.

We initiated a six-patient, Phase 1 clinical trial using porcine fetal neural cells in stroke patients in Boston, Massachusetts at Beth Israel Deaconess Medical Center and Brigham and Women's Hospital. In April 2000, this Phase 1 clinical trial was suspended by the FDA to allow investigation of the cause of two serious adverse events. At the time the trial was suspended we had treated 5 patients. Both patients who suffered adverse events have recovered from their adverse event. We have reviewed the scientific and clinical

Edgar Filing: DIACRIN INC /DE/ - Form 10-K

information relating to these adverse events and concluded that they were most likely associated with the surgical procedure used to implant the cells. This conclusion has been supported by an independent group of experts convened by Diacrin. We are now working with the FDA to obtain clearance to continue recruiting patients in this trial, which we expect will occur in the first half of 2002.

Porcine Neural Cells for Focal Epilepsy

Epilepsy is a chronic, recurrent disorder characterized by excessive neuronal discharge in the brain, causing muscle spasms or convulsions. Epileptic seizures are usually associated with some alteration of consciousness. Epilepsy is one of the most common neurological disorders and is estimated to affect 1.8 million people in the United States. The only currently available treatments for epilepsy are drug therapy and surgery. A number of anti-epileptic drugs are available to treat seizures. However, these drugs fail to control seizure activity in a significant number of patients and frequently cause side effects that range in severity from minimal impairment of the central nervous system to death from liver failure. By several estimates, approximately 200,000 patients with complex partial epilepsy have seizures that are not well-controlled with currently available drug therapy. The seizures are of many different types and arise as a result of diverse pathologies. Other therapies available to these patients are surgical removal of portions of the temporal or frontal lobe and vagal nerve stimulation through an implantable device. We believe that transplantation of porcine fetal neural cells will be preferable to removal of brain tissue if the transplantation is shown to be safe and efficacious.

Our initial therapeutic focus in this area is in the treatment of patients with complex partial seizures, which are characterized by a focal onset and a loss of consciousness. Because focal epilepsy is characterized by excessive electrical activity in a localized area of the brain and the spread of this activity through the brain, our approach to therapy is to transplant porcine fetal neural cells in order to exert an inhibitory effect on the hyperexcitable brain region.

We have initiated a six-patient, Phase 1 clinical trial of porcine fetal neural cells at Beth Israel Deaconess Medical Center and Brigham and Women's Hospital in Boston, SUNY Health Science Center in Syracuse, New York and Emory University in Atlanta, Georgia. As of March 15, 2002, we had treated three patients in this trial.

Porcine Neural Cells for Chronic Intractable Pain

Chronic intractable pain can be caused by neuropathologic processes in tissues and organs, or by prolonged dysfunction of peripheral or central nervous system pathways. Chronic intractable pain is characterized by the death of inhibitory neural cells in the spinal cord and cannot be relieved even with pain killers such as morphine. It is estimated that 500,000 individuals in the United States suffer from unrelieved chronic pain as a result of these peripheral neuropathies. Peripheral neuropathies can also be associated with diseases such as HIV, diabetes and cancer. Many patients with malignant disease develop chronic intractable pain, and the prevalence of severe pain in cancer patients increases as the disease progresses to the advanced stages. There are an estimated 1.6 million cancer patients who experience chronic intractable pain in the United States.

We intend to use porcine fetal neural cells to alleviate chronic pain by repopulating inhibitory neural cells to recover appropriate neurotransmission in the spinal cord. We have demonstrated in animal studies a favorable safety profile and survival of porcine fetal inhibitory neural cells transplanted into the dorsal horn of the spinal cord. Our Investigational New Drug Application, commonly referred to as IND, has been cleared by the FDA and we plan to initiate

Edgar Filing: DIACRIN INC /DE/ - Form 10-K

a six-patient, Phase 1 clinical trial in 2002 at New England Medical Center in Boston, Washington University Medical Center in St. Louis, Missouri and University of Washington in Seattle, Washington.

NeuroCell-PD for Parkinson's Disease

Parkinson's disease is a neurodegenerative disease that results from the loss of dopamine-producing neural cells within an area of the brain called the substantia nigra, causing the loss of coordinated muscular activity. The disease is generally characterized by progressively worsening physical conditions, including difficulty in movement, muscular rigidity, tremors and postural instability. In addition to a decreased quality of life, Parkinson's disease may also result in premature death. In the United States, there are approximately 500,000 people afflicted with Parkinson's disease. The majority of Parkinson's disease patients are first diagnosed between the ages of 45 and 65. NeuroCell-PD will be directed to the treatment of patients with advanced Parkinson's disease, which we estimate to be approximately 130,000 patients in the United States. We expect the prevalence of Parkinson's disease to increase with the increasing average age of the population.

Current therapies consist of administration of levodopa, commonly known as L-dopa, a precursor of dopamine, and dopamine analogues. However, L-dopa is only effective for a limited period of time, with most patients experiencing a progressive reduction in drug efficacy over a 10 to 15 year period, due to the cumulative loss of viable neural cells and tolerance to L-dopa. In addition, L-dopa therapy can result in severe side-effects, including uncontrolled movements, also known as dyskinesia, and hallucinations. No currently available therapy prevents progression of the neurological deficits caused by Parkinson's disease.

Clinical researchers have shown that transplantation of human fetal neural cells into Parkinson's disease patients is effective in treating the disease. For example, Swedish researchers have demonstrated survival and function of transplanted human fetal neural cells in Parkinson's disease patients in an ongoing study which commenced in 1989. This study has shown long-term survival of cells and improvements in patients' conditions. However, the lack of availability of human fetal neural cells and ethical concerns regarding the use of human fetal tissue limit its widespread clinical application. Moreover, even when available, the quality of human fetal neural cells is variable, which may limit the clinical effectiveness of this treatment.

Our approach to the treatment of Parkinson's disease is to produce and transplant NeuroCell-PD to replace the function of those neural cells damaged by the disease. We and our collaborators have shown in animal models that transplanted porcine fetal neural cells become integrated into the surrounding brain tissue and correct functional deficits. While NeuroCell-PD is not a cure for Parkinson's disease, the goal of this treatment is to significantly improve the clinical condition of patients with severe Parkinson's disease in order to allow them to function independently.

Our twelve-patient Phase 1 clinical trial of NeuroCell-PD, which completed enrollment in October 1996, was the first FDA-authorized trial involving transplantation of porcine cells into humans. Although the study was designed to evaluate the safety of NeuroCell-PD, we also evaluated its effects on the Parkinson's disease symptoms of the transplant recipients. Each of the twelve patients in the study received approximately 12 million cells transplanted unilaterally (one side of the brain). A histological study of one of the patients, who died of causes unrelated to the transplant, published in the March 1997 issue of Nature Medicine, demonstrated that porcine fetal neural cells survived and matured in his brain. This study marked the first published documentation of the survival of cells transplanted from another species into the human brain and the appropriate growth of the non-human neural cells in the

Edgar Filing: DIACRIN INC /DE/ - Form 10-K

brain of a Parkinson's disease patient.

Our clinical evaluators observed clinical improvement in the Parkinson's disease patients beginning approximately three months after transplantation. The patients who have been followed demonstrated statistically significant clinical improvement at one year, two years and three years post transplantation as measured by the Unified Parkinson's Disease Rating Scale.

In 1996, we formed Diacrin/Genzyme LLC with Genzyme, a joint venture to develop and commercialize NeuroCell-PD and a previously suspended product candidate, NeuroCell-HD. We refer to NeuroCell-PD and NeuroCell-HD as the joint venture's product candidates. In 1999, our joint venture with Genzyme completed accrual of patients in an 18-patient pivotal, randomized, double-blinded, placebo-controlled Phase 2 clinical trial involving the transplantation of NeuroCell-PD in conjunction with cyclosporine immunosuppression versus a control group. Each of the treated patients in this trial received approximately 48 million cells transplanted bilaterally (both sides of the brain). In March 2001, the trial was unblinded and we announced a preliminary analysis of the results. We did not see a statistically significant difference between the treated patients and the patients in the control group and, therefore, did not meet the primary endpoint in the trial. Development is currently suspended while we gather and evaluate additional clinical data.

Human Liver Cells for Cirrhosis

Cirrhosis of the liver is a common affliction in the United States, affecting an estimated 1.5 million individuals and leading to approximately 50,000 deaths annually. In cirrhosis, liver tissue is progressively lost due to accumulation of fibrous tissue and scarring, and liver function is compromised due to the degenerative changes. The most common causes of cirrhosis are viral hepatitis B and C infections and alcoholic liver disease. In the initial stages of the disease, the patient may experience jaundice and disorientation as liver function decreases. As the disease progresses, the patient will be hospitalized with increasing central nervous system effects, known as encephalopathy, which may lead to coma. The tremendous reserve of liver tissue allows the continued function of the organ, despite loss of up to 90% of the normal complement of liver cells. In advanced cirrhosis, little normal liver tissue remains.

The only effective therapy for advanced cirrhosis is liver transplantation. However, the United Network of Organ Sharing has documented a national lack of donor livers for transplantation, resulting in a waiting period of over two years for the average patient. Over 5,000 individuals await liver transplants in the United States and about 4,000 liver transplants are performed per year for all indications. Recently, artificial extra-corporeal liver assist devices, commonly known as ELAD, containing porcine or human liver cells attached to a dialysis cartridge have been used in an attempt to treat liver failure in advanced cirrhosis. Studies to date suggest that ELAD may improve some biochemical parameters such as ammonia levels but the devices have not resulted in increased survival. Human whole liver transplantation has also been used in both acute and chronic liver failure. In pilot clinical trials by others, transplantation of liver cells into either the liver or the spleen has been shown to be both safe and potentially effective in humans as a bridge to whole liver transplantation.

For chronic liver disease, we and others have shown in animal models that liver cell integration is possible when liver cells are injected into the liver or into the spleen. The spleen appears to be the preferred site due to the fibrosis and loss of blood supply to the cirrhotic liver. In animal models, transplantation of liver cells into the spleen is well described, and results in populating parts of the spleen with functioning liver cells that perform normal

liver functions.

We have initiated a six-patient, Phase 1 clinical trial of human liver cell transplantation for the treatment of cirrhosis in patients that have been listed for organ transplantation but are likely to wait at least one year before receiving a transplant. We believe these patients may benefit from the growth of transplanted liver cells in their liver or spleen leading to an increase in liver function. In addition, expansion of the cells may allow sufficient improvement to render a liver transplant unnecessary, unlike the case with ELAD which are used only as a bridge to transplantation. As part of the clinical trial, conventional immunosuppression will be compared to the use of our immunomodulation technology to determine whether graft protection is achieved by this technique. We are conducting this study in collaboration with Massachusetts General Hospital, New England Medical Center and at the University of Nebraska Medical Center in Omaha, Nebraska.

Porcine Liver Cells for Acute Liver Failure

Acute liver failure is a severe life-threatening disease that can result from alcohol consumption, viral infections, such as hepatitis B and C, and drugs or toxins that damage the liver. The clinical spectrum of acute liver disease can vary from patients with severe liver failure to patients without symptoms. The mortality from acute liver failure can be as high as 70%, with patients dying from associated complications. Acute liver failure results in approximately 63,000 deaths annually in the United States.

There is currently no therapy that is beneficial for all patients with acute liver failure. The best available therapy is liver transplantation. However, many patients are unable to qualify as candidates for liver transplantation due to multi-organ failure or active alcohol consumption. Current therapies attempt to treat complications arising from the acute condition, such as swelling of the brain, infections, and circulatory collapse.

Our approach to the treatment of acute liver failure is to support the patient by liver cell transplantation in order to provide liver function while allowing the patient's own liver to recover. In extensive studies in animal models, our scientists have shown that porcine liver cells can be isolated and infused into the recipient liver where they continue to function. Long-term survival and function of these cells has been demonstrated in these animal models. We believe liver cell transplantation could become a viable alternative to whole liver transplantation for the treatment of acute liver disease. We believe this approach would be preferable to transplantation of a whole liver, due to the difficulty of obtaining livers for transplantation as well as the expense and invasiveness of the procedure.

Porcine liver cells will be infused into the spleen or liver of these patients by minimally invasive procedures, thus avoiding a surgical procedure for these critically ill patients. In addition to the high level of quality control that can be maintained over the production of porcine liver cells, these cells also have the advantage of being resistant to infection by human hepatitis B and C viruses. Since many of the patients enrolled in this study are likely to carry these viruses, we believe the resistance of the porcine liver cells to infection may provide a further advantage over human liver transplantation in which hepatitis B and C reinfect donor livers.

We have initiated a six-patient, Phase 1 clinical trial and as of March 15, 2002 one patient has been treated. We are currently recruiting patients for this clinical trial which is being conducted at Massachusetts General Hospital, New England Medical Center and University of Nebraska Medical Center.

Edgar Filing: DIACRIN INC /DE/ - Form 10-K

Additional Liver Cell Applications

Successful delivery of liver cells to patients with alcoholic hepatitis or cirrhosis may provide the possibility of applying this technology to a variety of other diseases. The preparation of the cells and their delivery by minimally invasive procedures should be the same in most of these applications, thus providing a platform that may be used in multiple applications.

Additional applications include the use of liver cells for the treatment of metabolic diseases resulting from genetic mutations. Familial hypercholesterolemia is a disease caused by a defective receptor gene for low density lipoprotein, commonly referred to as LDL, that leads to elevated levels of LDL cholesterol and coronary disease at an early age. Familial hypercholesterolemia afflicts approximately 500,000 patients in the United States. Currently available drugs do not sufficiently lower circulating LDL cholesterol levels in approximately 20% of these patients, who may thus benefit from liver cell transplantation. Our scientists have shown through transplantation of liver cells into a rabbit model of this disease that porcine liver cells provide the animal with functional receptors that reduce serum LDL levels. There is a range of additional metabolic disorders that may be candidates for treatment by liver cell transplantation. Approximately 30,000 patients in the United States suffer from these metabolic disorders.

Human Muscle Cells for Cardiac Disease

Coronary heart disease is the leading cause of death in the United States, responsible for approximately 1 of every 5 deaths, or approximately 500,000 deaths each year. According to the American Heart Association, approximately 1 million heart attacks occur annually in the United States. Of the 800,000 patients who survive, approximately 200,000 will die within a year. The disease is caused by the accumulation of plaque, consisting of lipid deposits, macrophages and fibrous tissue, on the walls of vessels supplying blood to the heart muscle. Rupture of unstable plaques exposes substances that promote platelet aggregation and clot formation. The clot is composed of platelets, blood cells and fibrin that can block one or more of the coronary vessels, resulting in an inadequate supply of oxygen to the heart muscle. This highly active muscle is quickly damaged and the lesions are irreversible because heart muscle cells are not capable of cell division. The end result is an infarct, a damaged area of heart muscle in which scar tissue and fibrosis replace dead heart muscles, lowering the ability of the heart to contract and function.

Treatments to prevent tissue damage after a heart attack include drugs that break down fibrin clots and open up blocked arteries. These drugs have greatly influenced morbidity and mortality, but must be administered within a short interval after a heart attack to be effective. Even with current medical management, over one third of acute heart attacks are fatal. Cardiac catheterization and angioplasty to dislodge the clot and open the blocked vessel have proved effective in restoring blood flow, but cannot reverse preexisting tissue damage.

Our scientists have isolated and expanded muscle cells from human tissue and are studying the use of these cells for transplantation into damaged heart muscle. We believe that patients suffering from heart attacks would benefit if these muscle cells could repair their damaged hearts. These cells would be isolated from a muscle biopsy of a patient who had suffered a heart attack, thereby allowing transplantation of a patient's own muscle cells into his or her heart, which would avoid any rejection. In preclinical studies, we have demonstrated that muscle cells integrate into rodent heart muscle. The cells form stable grafts in a damaged heart.

We are currently conducting two Phase 1 clinical trials treating patients with damaged heart muscle. One clinical trial is treating patients at the same

Edgar Filing: DIACRIN INC /DE/ - Form 10-K

time they receive a ventricular assist device (VAD) while the other is treating patients as they undergo coronary bypass surgery (CABG). The VAD is implanted in patients in order to maintain heart function while they wait for a donor heart to become available. Our clinical trial involves implantation of 300 million myoblasts in six patients. After the patient is transplanted with a new heart, we are able to histologically examine the old heart. Preliminary results from one heart showed that cells survive and new blood vessel formation was stimulated. The clinical trial involving CABG patients is a 12-patient dose escalation trial, with safety being evaluated at doses ranging from 10 million to 300 million cells. It is planned that all patients will be enrolled in this trial by mid-2002.

Our clinical trials are being conducted at six medical centers, including Temple University Hospital in Philadelphia, Pennsylvania, the University of Michigan in Ann Arbor, Michigan, the UCLA Medical Center in Los Angeles, California, The Cleveland Clinic in Cleveland, Ohio, the Arizona Heart Institute in Phoenix, Arizona and Ohio State University in Columbus, Ohio. As of March 15, 2002, we had treated 13 patients in these clinical trials.

Manufacturing

The manufacture of most of our products will require the continuous availability of porcine tissue harvested under cGMP from pigs tested to be free of infectious agents. Our current source of pig facilities and services is obtained under contracts from Tufts University School of Veterinary Medicine and PharmServices, Inc., a division of Charles River Laboratories, Inc. We have also qualified several pig producers to provide pigs for our production processes.

We currently obtain the antibody fragments used in our immunomodulation technology from a contract manufacturer. We will evaluate on an ongoing basis the cost effectiveness and other relevant factors necessary to determine whether we should continue to obtain the antibody fragment from a contract manufacturer or produce them ourselves.

We isolate and prepare cell populations in our own clinical production facilities in Charlestown, Massachusetts. Our long-range plan is to expand our internal manufacturing capabilities, including the facilities necessary to test, isolate and package an adequate supply of finished cell products in order to meet our long-term clinical and commercial manufacturing needs.

Patents and Licenses

We intend to aggressively seek patent protection for any products we develop. We also intend to seek patent protection or rely upon trade secrets to protect certain of our technologies which will be used in discovering and evaluating new products. We have 16 issued U.S. patents and 20 patent applications pending with the United States Patent and Trademark Office. We have also filed foreign counterparts in the European Union and other selected countries. These applications seek composition-of-matter and use protection for the various products we have in development.

Massachusetts General Hospital has been awarded two patents in the United States covering the basic immunomodulation technology we use. Foreign counterparts of these patents have been filed in the European Union and other selected countries. Under an agreement with MGH, we have an exclusive, worldwide license to the technology and the inventions described in the patents, and all foreign counterparts, including any continuations, reissues or substitutions as well as any patents and equivalents which may mature from such patents, subject to the payment of royalties. Unless sooner terminated, our rights will continue, on a country by country basis, until the last patent expires. We or MGH may terminate the agreement, upon notice, in the event the other party defaults in its material obligations and has failed to cure this default within 60 days of

Edgar Filing: DIACRIN INC /DE/ - Form 10-K

receipt of written notice of the default.

To protect our trade secrets and other proprietary information, we require all employees, consultants, advisors and collaborators to enter into confidentiality agreements with us.

Sales and Marketing

We have not yet developed sales and marketing capabilities for our product candidates. We may form strategic alliances with established pharmaceutical or biotechnology companies in order to finance the development of certain of our products and, assuming successful development, to market such products. These alliances may enable us to expand or accelerate our product development efforts and also may provide us with access to established marketing organizations. Alternatively, we may decide to market some of our products on our own.

Government Regulation

Regulation by governmental authorities in the United States, the European Union member states and other foreign countries is a significant factor in the development, manufacture and marketing of our product candidates and in our ongoing research and product development activities. All of our products will require regulatory approval by governmental agencies prior to commercialization. In particular, human therapeutic products are subject to rigorous testing and approval procedures by the FDA and similar authorities in foreign countries. Various statutes and regulations govern the preclinical and clinical testing, manufacturing, labeling, distribution, advertising and sale of these products. The process of obtaining these approvals and the subsequent compliance with applicable statutes and regulations require the expenditure of substantial time and financial and other resources.

Preclinical testing is generally conducted in the laboratory on animals to evaluate the potential efficacy and the safety of a product. In the United States, the results of these studies are submitted to the FDA as part of an IND application, which must receive FDA clearance before human clinical testing can begin. Clinical trials are typically conducted in three phases which may overlap. Generally, in Phase 1, clinical trials are conducted with a small number of human subjects to determine the early safety profile. In Phase 2, clinical trials are conducted with groups of patients afflicted with the specific disease in order to determine preliminary efficacy, optimal treatment regimens and expanded evidence of safety. Where a product candidate is found to have an effect at an optimal dose and to have an acceptable safety profile in Phase 2, larger scale, multi-center, randomized and blinded Phase 3 clinical trials are conducted with patients afflicted with the target disease to further test for safety, to further evaluate clinical effectiveness and to obtain additional information for labeling. In addition, the FDA may request post-marketing (Phase 4) monitoring of the approved product, during which clinical data are collected on selected groups of patients to monitor longer-term safety.

Upon completion of Phase 3, for products regulated by the FDA's Center for Biologic Evaluation and Research, commonly referred to as CBER, the results of preclinical and clinical testing are submitted to the FDA in the form of a Biologics License Application, commonly referred to as BLA, for approval to manufacture and commence commercial sales. In responding to these applications, the FDA may grant marketing approval, request additional information or deny the application if it determined that the application does not satisfy the agency's regulatory approval criteria. We expect that CBER will regulate all of our product candidates.

Edgar Filing: DIACRIN INC /DE/ - Form 10-K

The nature of the marketing claims we will be permitted to use for labeling and advertising will be limited to those allowed in the FDA's approval. Claims beyond those approved would constitute a violation of the Food, Drug & Cosmetic Act or the FD&C Act. Noncompliance with the provisions of the FD&C Act or Public Health Service Act can result in, among other things, loss of approval, voluntary or mandatory product recall, seizure of products, fines, injunctions and civil or criminal penalties. Our advertising is also subject to regulation by the Federal Trade Commission under the FTC Act, which prohibits unfair methods of competition and unfair or deceptive acts or practices in or affecting commerce. Violation can result in a variety of enforcement actions including fines, injunctions and other remedies.

In the European member states and other foreign countries, our ability to market a product is contingent upon receiving marketing authorization from the appropriate regulatory authorities. The requirements governing the conduct of clinical trials, marketing authorization, pricing and reimbursement vary widely from country to country. Generally, we intend to apply for foreign marketing authorizations at a national level. However, within the European Union, procedures are available to companies wishing to market a product in one or all European Union member states. This centralized process is conducted through the European Medicines Evaluation Agency, known as the EMEA. The EMEA coordinates the regulatory process, while a body of experts drawn from member states undertakes the scientific assessment of the product and recommends whether a product satisfies the criteria of safety, quality and efficacy for approval. If the authorities are satisfied that adequate evidence of safety, quality and efficacy has been presented, a marketing authorization will be granted. This foreign regulatory approval process includes all of the risks associated with FDA approval set forth above. We may rely on licensees to obtain regulatory approval for marketing certain of our products in certain European Union member states or other foreign countries.

We are also subject to various federal, state and local laws, regulations and recommendations relating to safe working conditions, laboratory and manufacturing practices, the experimental use of animals and the use and disposal of hazardous or potentially hazardous substances, including radioactive compounds, infectious disease agents and recombinant DNA materials used in connection with our research work.

We intend to take advantage of the regulatory pathways which may provide expedited review of our cell transplantation products and allow limited cost recovery during the clinical research phase. These include: (1) expedited review for more effective or better tolerated therapies for serious conditions, commonly referred to as fast track designation, and (2) seeking approval for limited cost recovery during clinical testing under treatment IND status. We also intend to seek marketing exclusivity for products which qualify for orphan drug status, where appropriate.

Fast Track Designation. In 1997, Congress enacted the Food and Drug Administration Modernization Act, in part, to ensure the availability of safe and effective drugs by expediting the FDA review process for new products. This act establishes a statutory program for the approval of fast track products. A fast track product is defined as a new drug intended for the treatment of a serious or life-threatening condition, which demonstrates the potential to address unmet medical needs. Under the fast track program, the sponsor of a new drug may request the FDA to designate the drug as a fast track product at the time of the IND submission or after. If a preliminary review of the clinical data suggests that a fast track product may be effective, the FDA may initiate review of sections of a marketing application for a fast track product before the sponsor completes the application. NeuroCell-PD was granted fast track designation in 1999.

Treatment IND. Treatment IND is a mechanism established by the FDA in 1987

Edgar Filing: DIACRIN INC /DE/ - Form 10-K

which allows a company to distribute promising investigational therapies to patients outside of the established clinical trials and to charge a reasonable fee for such therapy. The disease must be serious or life-threatening and there must not be satisfactory alternative treatments. Treatment IND status has been applied to a variety of diseases including cancer, AIDS, Parkinson's disease, Alzheimer's disease and multiple sclerosis and to several anti-infectives for renal transplant patients. We intend to pursue this designation, where appropriate.

Orphan Drug Status. The Orphan Drug Act generally provides incentives to manufacturers to undertake development and marketing of products to treat relatively rare diseases or diseases where fewer than 200,000 persons in the United States would be likely to receive the treatment. A drug that receives orphan drug designation by the FDA and is the first product to receive FDA marketing approval for its product claim is entitled to a seven-year exclusive marketing period in the United States for that product claim. The FDA may terminate an orphan drug designation for many reasons, including if the manufacturer of the orphan drug product cannot provide an adequate supply of the product. Furthermore, a drug that the FDA considers to be different from a particular orphan drug is not barred from sale in the United States during such seven-year exclusive marketing period. Legislation to limit the marketing exclusivity provided for certain orphan drugs has occasionally been introduced in Congress. Although the outcome of that legislation is uncertain, future legislation may limit the incentives currently afforded to the developers of orphan drugs.

We have assigned to our joint venture with Genzyme the orphan drug designation we received from the FDA for the joint venture's product candidates. Our porcine fetal spinal cord cells for spinal cord injury product is also targeted to a population of less than 200,000 and, therefore, we will pursue orphan drug designation for this product candidate.

Competition

We believe that our ability to compete successfully will be based on our ability to create and maintain scientifically advanced technology, develop proprietary products and attract and retain qualified scientific personnel. In addition, we have to obtain adequate financing, patents, orphan drug designation or other protection for our products, and required regulatory approvals, and to manufacture and successfully market our products both independently and through collaborators.

The biopharmaceutical and pharmaceutical industries are characterized by intense competition. We compete against numerous companies, many of which have substantially greater financial and other resources than we do. Private and public academic and research institutions also compete with us in the research and development of human therapeutic products. In addition, many of our competitors have significantly greater experience than we do in the testing of pharmaceutical and other therapeutic products and obtaining FDA and other regulatory approvals of products for use in health care. Accordingly, our competitors may succeed in obtaining FDA approval for products more rapidly than we do. If we commence significant commercial sales of our products, we will also be competing with respect to manufacturing efficiency and marketing capabilities, areas in which we have limited or no experience.

Our products under development will compete with products and therapies which are either currently available or currently under development. Competition will be based, among other things, on efficacy, safety, reliability, price, availability of reimbursement and patent position. We are aware of other companies which are pursuing research and development of alternative products or

Edgar Filing: DIACRIN INC /DE/ - Form 10-K

technologies addressing the same disease categories as our development programs.

Employees

As of March 15, 2002, we had 30 full-time employees, 23 of whom were engaged in research, development, clinical and quality assurance/quality control activities. None of our employees are represented by a labor union or covered by a collective bargaining agreement.

Item 2. Properties

We lease a facility which contains approximately 25,000 square feet of space in Charlestown, Massachusetts. The current lease has a five-year term ending in 2006, providing for a base rental rate of approximately \$75,000 per month, plus applicable property taxes and insurance. We have the right to extend the lease an additional five years commencing in 2006. Our facilities are equipped with laboratory and cell culture capabilities sufficient to satisfy our research and development requirements for the foreseeable future and cell isolation capabilities sufficient to satisfy the clinical production requirements of several of our product candidates. To the extent that additional similar facilities may be required, we will be required to secure additional facilities or seek outside contractors to provide such capabilities.

Item 3. Legal Proceedings

We are currently not a party to any material legal proceedings.

Item 4. Submission of Matters to a Vote of Security Holders

No matters were submitted to a vote of our security holders, through solicitation of proxies or otherwise, during the last quarter of the fiscal year ended December 31, 2001.

Executive Officers of the Registrant

The following table sets forth the names, ages and positions of the directors, executive officers and other key employees of the Company:

Name	Age	Position
Thomas H. Fraser, Ph.D.	54	President and Chief Executive Officer; Director
E. Michael Egan	48	Chief Operating Officer
Kevin Kerrigan	31	Controller
Jonathan H. Dinsmore, Ph.D.	40	Senior Director of Cell Transplantation
Roger J. Gay, Ph.D.	48	Senior Director of Process Development
Abdellah Sentissi, Ph.D.	52	Senior Director of Quality Control and Quality
Douglas B. Jacoby, Ph.D.	41	Director of Research
Zola P. Horovitz, Ph.D. (1)	67	Director
John W. Littlechild (2)	50	Director
Stelios Papadopoulos, Ph.D. (1) (2)	53	Director

Edgar Filing: DIACRIN INC /DE/ - Form 10-K

Joshua Ruch (1) 52 Director

Henri A. Termeer (2) 55 Director

(1) Member of Audit Committee

(2) Member of Compensation Committee

Thomas H. Fraser, Ph.D., has served as our President and Chief Executive Officer and as a Director since 1990. Dr. Fraser was previously Executive Vice President, Corporate Development, for Repligen Corporation, a biopharmaceutical company. Dr. Fraser was the founding Vice President for Research and Development at Repligen in 1981 and served as Executive Vice President from 1982 through 1990 as well as Chief Technical Officer from 1982 through 1988. Prior to joining Repligen, Dr. Fraser headed the recombinant DNA research group in Pharmaceutical Research and Development at The Upjohn Company, a pharmaceutical company. Dr. Fraser received his Ph.D. in Biochemistry from the Massachusetts Institute of Technology and was a Damon Runyon-Walter Winchell Cancer Fund Postdoctoral Fellow at The University of Colorado.

E. Michael Egan was promoted to Chief Operating Officer in January 2001. Prior to that, Mr. Egan had served as our Senior Vice President, Corporate Development, since 1993. Mr. Egan joined us from Repligen, where he was employed from 1983 to 1993, and since 1989 had been Vice President of Business Development. He was also a member of the Board of Directors of Repligen Clinical Partners, L.P., and the Secretary/Treasurer of Repligen Sandoz Research Corporation. Mr. Egan's previous positions at Repligen include Director of Business Development and Manager of Business Development. Prior to joining Repligen in 1983, Mr. Egan was a laboratory supervisor at Dana-Farber Cancer Institute, Division of Medicine. He received a B.S. in biology from Boston College and a Certificate of Special Studies in Administration and Management from Harvard University in 1986.

Kevin Kerrigan has served as our Controller since November 1998. Mr. Kerrigan joined us in 1997 as Accounting Manager. From 1993 to 1997 Mr. Kerrigan was a member of the professional staff of Price Waterhouse LLP. Mr. Kerrigan received a B.S. degree in accounting from Merrimack College and was awarded a CPA certificate from the Commonwealth of Massachusetts in 1993.

Jonathan H. Dinsmore, Ph.D., has been Senior Director of Cell Transplantation Research since April 1999. He joined Diacrin in 1992 as a Research Scientist and was subsequently promoted to Principal Investigator and then Director of Cell Transplantation Research. Dr. Dinsmore was previously a Postdoctoral Fellow of the American Cancer Society in the Biology department at the Massachusetts Institute of Technology from 1988 to 1992. He received a Ph.D. in biology from Dartmouth College, where he was a Presidential Scholar and recipient of a Kramer Fellowship. Dr. Dinsmore has worked on National Science Foundation-sponsored research projects at the Marine Biological Laboratories in Woods Hole, Massachusetts and at a United States research base in Antarctica.

Roger J. Gay, Ph.D., has been Senior Director of Process Development since February 2000. Dr. Gay was hired by Diacrin in 1993 as Director of Process Development. From 1986 through 1993, he was Director of Product Development at Organogenesis, Inc. Dr. Gay's previous positions were Manager of a Contract Research and Cytotoxicity Testing Laboratory and Director of Product Development at Bioassay Systems Research Corporation from 1982 to 1986. He received a B.A. in chemistry from the College of the Holy Cross in 1975 and a Ph.D. in biochemistry from the University of Rochester in 1981. From 1981 through 1983, he was a postdoctoral research fellow in the Department of Microbiology and Molecular Genetics at Harvard Medical School.

Edgar Filing: DIACRIN INC /DE/ - Form 10-K

Abdellah Sentissi, Ph.D., has been Senior Director of Quality Control and Quality Assurance since February 2000. Dr. Sentissi came to Diacrin in 1995 as Director of Quality Control and Quality Assurance. Prior to joining Diacrin, from 1992 to 1995, he served as the Director of QC/QA and Technical Affairs at Endocon, Inc. From 1985 through 1992, he was the Chief of Quality Control at Massachusetts Biologics Laboratories. He received a pharmacy degree in 1973 and a biology degree in 1976 from the University of Paul Sabatier, Toulouse, France, and a Ph.D. in biomedical sciences from Northeastern University in 1984. From 1984 through 1985, he was a postdoctoral research fellow in the Department of Clinical Chemistry at Northeastern University. He has been a lecturer in pharmaceutical biotechnology at the School of Pharmacy at Northeastern University since 1990.

Douglas B. Jacoby, Ph.D., was appointed Director of Research in April 1999. He joined Diacrin in 1993 as a Research Scientist and was subsequently promoted to Principal Investigator. While a postdoctoral fellow in the Biochemistry department at Brandeis University, Dr. Jacoby was awarded a fellowship from the NIH. He received his Ph.D. in Biochemistry from the University of Minnesota with awards from the NIH and a Doctoral Dissertation Fellowship. He was graduated with an A.B. in Biology from Kenyon College.

Zola P. Horovitz, Ph.D., has served as a Director of Diacrin since 1994. Dr. Horovitz was Vice President, Business Development and Planning at Bristol-Myers Squibb Pharmaceutical Group from 1991 until 1994 and was Vice President, Licensing from 1989 to 1991. Prior to 1989, Dr. Horovitz spent 30 years as a member of the Squibb Institute for Medical Research, most recently as Vice President, Research Planning. Dr. Horovitz is also a director of Avigen, Inc., BioCryst Pharmaceuticals, Genaera Pharmaceuticals, Paligent, Synaptic Pharmaceuticals, Inc. and Palatin Technologies. Dr. Horovitz received his Ph.D. from the University of Pittsburgh.

John W. Littlechild has been a Director of Diacrin since 1992. Mr. Littlechild is associated with several venture capital partnerships managed by HealthCare Ventures LLC, including HealthCare Ventures II, L.P., HealthCare Ventures III, L.P., and HealthCare Ventures IV, L.P. Mr. Littlechild currently serves as Vice Chairman of HealthCare Ventures LLC. From 1984 to 1991, Mr. Littlechild was a Senior Vice President of Advent International Corporation, a venture capital company in Boston and London. Prior to working at Advent in Boston, Mr. Littlechild was involved in establishing Advent in the United Kingdom. From 1980 to 1982, Mr. Littlechild served as Assistant Vice President for Citicorp Venture Corporation, a venture capital company, in London, prior to which he worked with ICI Ltd., an agro-chemical company, and Rank Xerox, an office equipment company, in marketing and financial management. Mr. Littlechild holds a B.Sc. (1st class honors) from the University of Manchester and an MBA from Manchester Business School. Mr. Littlechild serves on the board of directors of various health care and biotechnology companies, including Dyax, a biotechnology company, and Orthofix International N.V., a medical device company. Mr. Littlechild also serves on several Boards for the Harvard Medical School including the Executive Committee of the Board of Fellows, the Science and Technology Committee, and is Chairman of the Microbiology Department Advisory Board. He is also a member of the Board of Visitors of the Beth Israel Deaconess Center for Research and Education.

Stelios Papadopoulos, Ph.D., has been a Director of Diacrin since 1991. Dr. Papadopoulos is a Managing Director in the investment banking division at SG Cowen Securities Corporation focusing on the biotechnology and pharmaceutical sectors. Prior to joining SG Cowen Securities Corporation in February 2000, he spent 13 years as an investment banker at PaineWebber, where he was most recently Chairman of PaineWebber Development Corp., a PaineWebber subsidiary. Prior to becoming an investment banker he spent two years as a biotechnology analyst, first at Donaldson, Lufkin & Jenrette and subsequently at Drexel

Edgar Filing: DIACRIN INC /DE/ - Form 10-K

Burnham Lambert, where he was elected to the Institutional Investor 1987 All-American Research Team. Before coming to Wall Street in 1985, Dr. Papadopoulos was on the faculty of the Department of Cell Biology at New York University Medical Center. He continues his affiliation with NYU Medical Center as an Adjunct Associate Professor of Cell Biology. Dr. Papadopoulos holds a Ph.D. in biophysics and an MBA in finance, both from New York University. He is a founder and Chairman of the Board of Exelixis, Inc., and sits on the board of several private companies in the biotechnology sector.

Joshua Ruch has been a Director of Diacrin since March 1998. Mr. Ruch is the Chairman and Chief Executive Officer of Rho Capital Partners, Inc., an international investment management firm which he co-founded in 1981. Prior to founding Rho, Mr. Ruch was employed in investment banking at Salomon Brothers and Bache Halsey Stuart, Inc. Mr. Ruch received a B.S. degree in electrical engineering from the Israel Institute of Technology (Technion) and an MBA from the Harvard Business School. Mr. Ruch also serves on the board of directors of 3-Dimensional Pharmaceuticals, Inc. as well as several private companies in the technology sector.

Henri A. Termeer has been a Director of Diacrin since December 1996. Mr. Termeer has served as President and Director of Genzyme Corporation, a biopharmaceutical company, since 1983, as Chief Executive Officer since 1985 and as Chairman of the Board since 1988. For ten years prior to joining Genzyme, Mr. Termeer held various management positions at Baxter Travenol Laboratories, Inc., a manufacturer of human health care products. Mr. Termeer also serves on the boards of directors of Abiomed, Inc., AutoImmune, Inc., Genzyme Transgenics Corporation and is a trustee of Hambrecht & Quist Healthcare Investors and Hambrecht & Quist Life Sciences Investors.

Directors are elected annually by our stockholders and hold office until the next annual meeting of stockholders or until their resignation or removal. Each executive officer serves at the discretion of the board of directors and holds office until his or her successor is elected and qualified or until his or her earlier resignation or removal. There are no family relationships among any of our directors or executive officers.

Scientific Advisory Board

Our scientific advisory board is a multi-disciplinary assemblage of scientists and physicians in the fields of transplantation, immunology, endocrinology, neurophysiology and neuromuscular physiology, transplantation biology and surgery. The scientific advisory board meets regularly to review and evaluate our research programs and advise us with respect to technical matters. The members of the scientific advisory board are as follows:

Name	Member Since	Position
Hugh Auchincloss, Jr., M.D.	1992	Professor of Surgery, Harvard Medical School; Director, Kidney Transplantation, Brigham and Women's Hospital; Surgical Director, Pancreas Transplantation and Visiting Surgeon, Massachusetts General Hospital
Jay A. Berzofsky, M.D., Ph.D.	1992	Chief, Molecular Immunogenetics

Edgar Filing: DIACRIN INC /DE/ - Form 10-K

		and Vaccine Research Section, Metabolism Branch, National Cancer Institute, National Institutes of Health
Robert H. Brown, Jr., M.D., D.Phil.	1992	Director of Cecil B. Day Laboratory for Neuromuscular Research, Associate in Neurology, Massachusetts General Hospital; Professor of Neurology, Harvard Medical School
Laurie H. Glimcher, M.D.	1993	Professor of Immunology, Department of Immunology and Infectious Diseases, Harvard School of Public Health; Professor of Medicine, Harvard Medical School
Ronald D. McKay, Ph.D.	1998	Chief, Laboratory of Molecular Biology, National Institute of Neurological Disorders and Stroke, National Institutes of Health
David H. Sachs, M.D.	1990	Director, Transplantation Biology Research Center, Massachusetts General Hospital; Paul S. Russell/ Warner-Lambert Professor of Surgery (Immunology), Harvard Medical School

PART II

Item 5. Market for Registrant's Common Stock and Related Stockholder Matters

Our common stock is traded on the NASDAQ National Market under the symbol DCRN. The following table sets forth for the periods indicated the high and low sale prices for the common stock during 2000 and 2001 as reported on the Nasdaq National Market:

	High	Low
Fiscal Year 2000		
First Quarter	19.6875	5.7500
Second Quarter	13.5000	6.3125
Third Quarter	9.6250	6.2500
Fourth Quarter	7.6250	3.8750
Fiscal Year 2001		
First Quarter	6.5000	1.1250

Edgar Filing: DIACRIN INC /DE/ - Form 10-K

Second Quarter	2.9700	1.0500
Third Quarter	2.2000	1.5000
Fourth Quarter	2.1500	1.5000

As of March 15, 2002 there were approximately 105 record holders of our common stock and approximately 3,500 beneficial owners of our common stock.

We have never declared or paid cash dividends on our capital stock. We intend to retain earnings, if any, for use in our business and do not anticipate declaring or paying any cash dividends in the foreseeable future.

We did not sell any equity securities during the quarter ended December 31, 2001 that were not registered under the Securities Act.

Item 6. Selected Financial Data

The selected financial data set forth below as of December 31, 2000 and 2001 and for each of the three years in the period ended December 31, 2001 are derived from our financial statements which have been audited by Arthur Andersen LLP, independent public accountants, and which are included elsewhere in this Annual Report on Form 10-K. The selected financial data set forth below as of December 31, 1997, 1998 and 1999 and for the years ended December 31, 1997 and 1998 are derived from our financial statements which have been audited by Arthur Andersen LLP and are not included herein. The data set forth below should be read in conjunction with our financial statements, related notes thereto and "Management's Discussion and Analysis of Financial Condition and Results of Operations" included elsewhere in this Annual Report on Form 10-K.

	Year Ended December 31,				
	1997	1998	1999	2000	2001
	----	----	----	----	----
Statement of Operations Data:	(in thousands, except share and per share data)				
REVENUES:					
Research and development	\$ 4,763	\$ 3,623	\$ 2,971	\$ 2,082	\$ 737
Investment income	1,302	1,576	1,323	3,125	3,150
	-----	-----	-----	-----	-----
Total revenues	6,065	5,199	4,294	5,207	3,887
	-----	-----	-----	-----	-----
OPERATING EXPENSES:					
Research and development	6,863	7,372	5,921	5,997	6,350
General and administrative	1,460	1,484	1,398	1,348	1,624
Interest expense	93	89	47	30	14
	-----	-----	-----	-----	-----
Total operating expenses	8,416	8,945	7,366	7,375	7,988
	-----	-----	-----	-----	-----
Equity in operations of joint venture	-	(1,084)	(1,688)	(1,369)	(547)
	-----	-----	-----	-----	-----

Edgar Filing: DIACRIN INC /DE/ - Form 10-K

Net loss	\$ (2,351)	\$ (4,830)	\$ (4,760)	\$ (3,537)	\$ (4,648)
	=====	=====	=====	=====	=====
Net loss per common share:					
Basic and diluted	\$ (.18)	\$ (.34)	\$ (.33)	\$ (.21)	\$ (.26)
	=====	=====	=====	=====	=====
Weighted average shares outstanding(1):					
Basic and diluted	13,235,286	14,156,179	14,364,154	17,073,194	17,914,889
	=====	=====	=====	=====	=====

	At December 31,				
Balance Sheet Data:	1997	1998	1999	2000	2001
	----	----	----	----	----
Cash, cash equivalents and investments	\$ 21,347	\$ 26,270	\$ 21,420	\$ 54,607	\$ 49,727
Working capital	9,551	21,812	17,133	32,502	41,078
Total assets	22,780	27,484	22,366	55,793	50,681
Long-term debt	672	392	249	119	-
Stockholders' equity	20,204	24,845	20,145	53,766	49,146

(1) Computed as described in Note 2 (d) of Notes to Financial Statements.

Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations

Overview

Since our inception, we have principally focused our efforts and resources on research and development of cell transplantation technology for treating human diseases that are characterized by cell dysfunction or cell death and for which current therapies are either inadequate or nonexistent. Our primary source of working capital to fund those activities has been proceeds from the sale of equity and debt securities. In addition, since October 1, 1996, we have received funding from our joint venture with Genzyme in support of the joint venture's product development programs. We have not received any revenues from the sale of products to date and do not expect to generate product revenues for the next several years. We have experienced fluctuating operating losses since inception and expect that the additional activities required to develop and commercialize our products will result in increasing operating losses for the next several years. At December 31, 2001, we had an accumulated deficit of \$52.4 million.

In 1996, we formed a joint venture with Genzyme to develop and commercialize the joint venture's product candidates. We are currently responsible for funding 25% of the development and commercialization costs of the joint venture and will share all costs in excess of \$50 million equally with Genzyme. As of December 31, 2001, approximately \$33.0 million had been contributed to the joint venture by Genzyme and approximately \$7.6 million had been contributed by us. Genzyme's President and Chief Executive Officer is a director of the Company.

Edgar Filing: DIACRIN INC /DE/ - Form 10-K

Critical Accounting Policies

Our significant accounting policies are discussed in Note 2 of our audited financial statements which are included in this Form 10-K. We believe our most critical accounting policies are those that dictate how we recognize revenue and expense related to the joint venture's activity. We record as research and development expense all costs related to the joint venture's product candidates incurred by us on behalf of the joint venture. We then recognize research and development revenue equal to the amount of reimbursement received by us from the joint venture out of funds contributed by Genzyme. We do not recognize research and development revenue for amounts we receive from the joint venture out of funds contributed by us. As Genzyme incurs costs on behalf of the joint venture that we are obligated to fund, we recognize an expense in our statement of operations captioned "Equity in operations of joint venture."

Results of Operations

Year Ended December 31, 2001 Versus Year Ended December 31, 2000

Research and development revenues were approximately \$737,000 for the year ended December 31, 2001 and \$2.1 million for the year ended December 31, 2000. Revenues for both years were comprised entirely of revenue from the joint venture. The decrease in revenues was primarily a result of a decrease in clinical production activity related to our joint venture with Genzyme.

Investment income of \$3.1 million for the years ended December 31, 2001 and 2000 remained relatively unchanged. We expect our investment income in 2002 will decrease due to a drop in interest rates.

Research and development expenses were \$6.4 million for the year ended December 31, 2001 versus \$6.0 million for the year ended December 31, 2000. The increase in research and development expenses was primarily due to an increase in the costs associated with sponsoring and managing our clinical trials.

General and administrative expenses were \$1.6 million for the year ended December 31, 2001 versus \$1.3 million for the year ended December 31, 2000. The increase in general and administrative expenses was primarily due to an increase in personnel costs related to an executive retention plan and an increase in professional fees incurred as we evaluated strategic relationships.

Interest expense was \$14,000 for the year ended December 31, 2001 and \$30,000 for the year ended December 31, 2000. The decrease in 2001 was due to the scheduled pay down of lease and loan debt outstanding.

For the year ended December 31, 2001, we recorded a \$547,000 charge related to our equity in the operations of the joint venture compared to a \$1.4 million charge for the year ended December 31, 2000. This expense related to funds contributed by us to the joint venture that were used to fund expenses incurred by Genzyme on behalf of the joint venture. The decreased charge in 2001 was primarily due to a decrease in clinical activity performed by Genzyme on behalf of the joint venture.

We incurred a net loss of approximately \$4.6 million for the year ended December 31, 2001 versus a net loss of approximately \$3.5 million for the year ended December 31, 2000.

Year Ended December 31, 2000 Versus Year Ended December 31, 1999

Research and development revenues were approximately \$2.1 million for the year ended December 31, 2000 and \$3.0 million for the year ended December 31, 1999. Revenues for both years were comprised entirely of revenue from the joint venture. The decrease in revenues was primarily a result of a decrease in

Edgar Filing: DIACRIN INC /DE/ - Form 10-K

clinical production activity related to our joint venture with Genzyme. The joint venture completed accruing patients into its Phase 2 clinical trial for NeuroCell-PD in 1999.

Investment income was \$3.1 million for the year ended December 31, 2000 versus \$1.3 million for the year ended December 31, 1999. The increase in 2000 was due to greater cash balances available for investment in 2001 as a result of our public stock offering completed in March 2000.

Research and development expenses of \$6.0 million for the year ended December 31, 2000 and \$5.9 million for the year ended December 31, 1999, remained relatively unchanged between the periods.

General and administrative expenses of \$1.3 million for the year ended December 31, 2000 and \$1.4 million for the year ended December 31, 1999, remained relatively unchanged between the periods.

Interest expense was \$30,000 for the year ended December 31, 2000 and \$47,000 for the year ended December 31, 1999. The decrease in 2000 was due to the scheduled pay down of lease and loan debt outstanding.

For the year ended December 31, 2000, we recorded a \$1.4 million charge related to our equity in the operations of the joint venture compared to a \$1.7 million charge for the year ended December 31, 1999. This expense related to funds contributed by us to the joint venture that were used to fund expenses incurred by Genzyme on behalf of the joint venture. The decreased charge in 2000 was primarily due to a decrease in clinical activity performed by Genzyme on behalf of the joint venture as the joint venture completed recruiting patients into its Phase 2 clinical trial in 1999.

We incurred a net loss of approximately \$3.5 million for the year ended December 31, 2000 versus a net loss of approximately \$4.8 million for the year ended December 31, 1999.

Liquidity and Capital Resources

We have financed our activities primarily with the net proceeds from the sale of equity and debt securities aggregating \$102.0 million and with interest earned thereon. In addition, we have recorded approximately \$15.2 million in revenue from our joint venture since it commenced on October 1, 1996. At December 31, 2001, we had cash and cash equivalents, short-term investments and long-term investments aggregating approximately \$49.7 million.

Net cash used in operating activities was \$3.9 million for the year ended December 31, 2001, \$2.5 million for the year ended December 31, 2000 and \$2.9 million for the year ended December 31, 1999. Cash used in operations for the years ended December 31, 2001, 2000 and 1999 was primarily attributable to our net loss, offset in part by our equity in operations of the joint venture.

Net cash provided by investing activities was \$1.4 million for the year ended December 31, 2001. Net cash used in investing activities was \$25.6 million for the year ended December 31, 2000. Net cash provided by investing activities was \$344,000 for the year ended December 31, 1999. Net cash provided by investing activities for the year ended December 31, 2001, was primarily attributable to a decrease in long-term investments offset by an increase in short-term investments. Net cash used in investing activities for the year ended December 31, 2000, was primarily attributable to an increase in short-term investments and long-term investments. The increase in investments was due to our public offering of Common Stock in March 2000. Net cash provided by investing activities for the year ended December 31, 1999 was primarily attributable to a decrease in short-term investments and the return of capital for services provided on behalf of our joint venture, offset in part by our

Edgar Filing: DIACRIN INC /DE/ - Form 10-K

investment in our joint venture.

Net cash used in financing activities was \$102,000 for the year ended December 31, 2001. Net cash provided by financing activities was \$37.0 million for the year ended December 31, 2000. Net cash used in financing activities was \$220,000 for the year ended December 31, 1999. Net cash used in financing activities for the year ended December 31, 2001 was primarily attributable to principal payments made towards long-term debt. Net cash provided by financing activities for the year ended December 31, 2000 was primarily attributable to net proceeds from the sale of common stock in a public offering in March 2000. Net cash used in financing activities for the year ended December 31, 1999 was primarily attributable to principal payments made towards long-term debt.

In November 1997, we borrowed \$650,000 at the prime rate plus 0.5% (5.25% at December 31, 2001) under an unsecured five-year term loan with a bank to finance our biomedical animal facility acquired during 1997. As of December 31, 2001, we owed \$119,000 under this term loan. We had no material commitments for capital expenditures as of December 31, 2001. In October 2000, we exercised the first of two options we have to extend the lease of a facility an additional five years. During the extension period, which began in October 2001, we will pay annual rent of approximately \$898,000.

We believe that our existing funds will be sufficient to fund our operating expenses and capital requirements as currently planned for the foreseeable future. However, our cash requirements may vary materially from those now planned because of results of research and development, the scope and results of preclinical and clinical testing, any termination of the joint venture, relationships with future strategic partners, changes in the focus and direction of our research and development programs, competitive and technological advances, the FDA's regulatory process, the market acceptance of any approved products and other factors.

We expect to incur substantial additional costs, including costs related to ongoing research and development activities, preclinical studies, clinical trials, expanding our cell production capabilities and the expansion of our laboratory and administrative activities. Therefore, in order to achieve commercialization of our potential products, we may need substantial additional funds. We cannot assure you that we will be able to obtain the additional funding that we may require on acceptable terms, if at all.

Diacrin/Genzyme LLC Financial Statements

For the year ended December 31, 2000, our equity in operations of the joint venture exceeded 20% of our net loss. Accordingly, pursuant to the rules of the Securities and Exchange Commission, our prior year Annual Report on Form 10-K included separate audited financial statements for the joint venture. For the year ended December 31, 2001, our equity in operations of the joint venture did not exceed 20% of our net loss. As a result, the current year financial information with respect to the joint venture presented in this Annual Report on Form 10-K is unaudited.

Recently Issued Accounting Pronouncements

In August 2001, the FASB issued SFAS No. 144, Accounting for the Impairment or Disposal of Long-Lived Assets. This statement supersedes SFAS No. 121, Accounting for the Impairment of Long-Lived Assets and for Long-Lived Assets to Be Disposed Of, and portions of Accounting Principles Bulletin Opinion 30, Reporting the Results of Operations. This statement provides a single accounting model for long-lived assets to be disposed of and significantly changes the criteria that would have to be met to classify an asset as held-for-sale. In addition, it requires expected future operating losses from discontinued operations to be displayed in the period(s) in which the losses are

Edgar Filing: DIACRIN INC /DE/ - Form 10-K

incurred, rather than as of the measurement date as presently required. This statement is effective for fiscal years beginning after December 15, 2001. We adopted SFAS No. 144 as of January 1, 2002 and, based on current circumstances, we do not expect the adoption of the statement will have a material impact on our financial statements.

Certain Factors That May Affect Future Results

The following important factors, among others, could cause actual results to differ materially from those contained in forward-looking statements made in this Annual Report on Form 10-K or presented elsewhere by management from time to time. The forward-looking statements contained in this Annual Report on Form 10-K represent our expectations as of March 28, 2002, the date our Annual Report on Form 10-K was filed with the SEC. Subsequent events will cause our expectations to change. However, while we may elect to update these forward-looking statements, we specifically disclaim any obligation to do so. See "Cautionary Note Regarding Forward-Looking Statements."

Risks Related to Our Business, Industry and Strategy

We have not successfully commercialized any products to date and, if we do not successfully commercialize any products, we will not be profitable

Neither we nor any other company has received regulatory approval to market the types of products we are developing. The products that we are developing will require additional research and development, clinical trials and regulatory approval prior to any commercial sale. Our product candidates are currently in early phase clinical trials or in the preclinical stage of development. Our products may not be effective in treating any of our targeted disorders or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may prevent or limit their commercial use.

We currently have no products for sale and do not expect to have any products available for sale for several years. If we are not successful in developing and commercializing any products, we will never become profitable.

The evaluation of the unblinded data from our Phase 2 clinical trial of NeuroCell-PD may not support further development

In March 2001, we unblinded our Phase 2 clinical trial of NeuroCell-PD and announced a preliminary analysis of the results. We did not see a statistically significant difference between the treated patients and the patients in the control group and, therefore, did not meet the primary endpoint in the trial. While we are still evaluating the data from this clinical trial, it is possible that further clinical development of NeuroCell-PD by the joint venture will not be supported by Genzyme, or that we may choose to discontinue development or modify the clinical trial protocols, which could result in the termination of or significant delay in the progress of the NeuroCell-PD development program or the termination of the joint venture.

Our cell transplantation technology is complex and novel and there are uncertainties as to its effectiveness

We have concentrated our efforts and therapeutic product research on cell transplantation technology, and our future success depends on the successful development of this technology. Our principal approach is based upon xenotransplantation, or the transplantation of cells, tissues or organs from one species to another. Our product candidates generally involve the transplantation

Edgar Filing: DIACRIN INC /DE/ - Form 10-K

of porcine (pig) neural cells into humans. Xenotransplantation is an emerging technology with limited clinical experience. Neither the FDA nor any foreign regulatory body has approved any xenotransplantation-based therapeutic product for humans.

Our technological approaches may not enable us to successfully develop and commercialize any products. If our approaches are not successful, we may be required to change the scope and direction of our product development activities. In that case, we may not be able to identify and implement successfully an alternative product development strategy.

Xenotransplantation involves risks which have resulted in additional FDA oversight and which in the future may result in additional regulation

Xenotransplantation poses a risk that viruses or other animal pathogens may be unintentionally transmitted to a human patient. The FDA requires us to perform tests to determine whether infectious agents, including porcine endogenous retroviruses, referred to as PERV, are present in patients who have received porcine cells. While PERV has not been shown to cause any disease in pigs, it is not known what effect, if any, PERV may have on humans. We have performed tests on patients who have received our porcine cells. No PERV has been detected to date, but we cannot assure you that we will not detect PERV or another infectious agent in the future.

The FDA requires lifelong monitoring of porcine cell transplant recipients. If PERV or any other virus or infectious agent is detected in tests or samples, the FDA may require us to halt our clinical trials and perform additional tests to assess the risk to patients of infection. This could result in additional costs to us and delays in the trials of our porcine cell products. Furthermore, even if patients who have received our porcine cells remain PERV-free, we could be adversely affected if PERV is detected in patients who receive porcine cells provided by others.

In January 2001, the FDA issued definitive regulatory guidelines for xenotransplantation titled "PHS Guideline on Infectious Disease Issues in Xenotransplantation." We cannot assure you that we will be able to comply with these guidelines.

We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do

The products we are developing compete with existing and new products being developed by pharmaceutical, biopharmaceutical and biotechnology companies, as well as universities and other research institutions. Many of our competitors are substantially larger than we are and have substantially greater capital resources, research and development staffs and facilities than we have. Efforts by other biotechnology or pharmaceutical companies could render our products uneconomical or result in therapies for the disorders we are targeting that are superior to any therapy we develop. Furthermore, many of our competitors are more experienced in product development and commercialization, obtaining regulatory approvals and product manufacturing. As a result, they may develop competing products more rapidly and at a lower cost. These competitors may discover, develop and commercialize products which render non-competitive or obsolete the products that we are seeking to develop and commercialize.

If the market is not receptive to our products upon introduction, our products may not achieve commercial success

The commercial success of any of our products will depend upon their acceptance by patients, the medical community and third-party payors. Among the factors that we believe will materially affect acceptance of our products are:

Edgar Filing: DIACRIN INC /DE/ - Form 10-K

- the timing of receipt of marketing approvals and the countries in which those approvals are obtained;
- the safety and efficacy of our products;
- the need for surgical administration of our products;
- problems encountered in the field of xenotransplantation;
- the success of physician education programs;
- the cost of our products which may be higher than conventional therapeutic products because our products involve surgical transplantation of living cells; and
- the availability of government and third-party payor reimbursement of our products.

Risks Relating to Clinical and Regulatory Matters

If our clinical trials are not successful for any reason, we will not be able to develop and commercialize any related products

In order to obtain regulatory approvals for the commercial sale of our product candidates, we will be required to complete extensive clinical trials in humans to demonstrate the safety and efficacy of the products. We have limited experience in conducting clinical trials.

The submission of an investigational new drug application, or IND, may not result in FDA authorization to commence clinical trials. If clinical trials begin, we may not complete testing successfully within any specific time period, if at all, with respect to any of our product candidates. Furthermore, we or the FDA may suspend clinical trials at any time on various grounds, including a finding that the patients are being exposed to unacceptable health risks. Clinical trials, if completed, may not show any potential product to be safe or effective. Thus, the FDA and other regulatory authorities may not approve any of our product candidates for any disease indication.

The rate of completion of clinical trials depends in part upon the rate of enrollment of patients. Patient enrollment is a function of many factors, including the size of the patient population, the proximity of patients to clinical sites, the eligibility criteria for the study, the existence of competitive clinical trials and the availability of alternative treatments. In particular, the patient population for some of our potential products is small. Delays in planned patient enrollment may result in increased costs and program delays.

We rely on third-party clinical investigators to conduct our clinical trials. As a result, we may encounter delays outside of our control.

We may not be able to reinitiate a clinical trial that has been suspended by the FDA

Clinical trials are subject to ongoing review by the FDA. The FDA has the authority to suspend a clinical trial for various reasons, as they did in April 2000 with respect to our clinical trial using porcine neural cells to treat stroke patients. Because our products are novel and complex, getting the FDA to lift a suspension could result in significant program delays and additional costs to us. It is possible that we may not be able to obtain permission from the FDA to continue a clinical trial that has been suspended. Cost increases and ongoing delays as a result of an FDA suspension could result in our decision to postpone pursuing certain product candidates.

Edgar Filing: DIACRIN INC /DE/ - Form 10-K

The regulatory approval process is costly and lengthy and we may not be able to successfully obtain all required regulatory approvals

We must obtain regulatory approval for each of our product candidates before we can market or sell it. We may not receive regulatory approvals to conduct clinical trials of our products or to manufacture or market our products. In addition, regulatory agencies may not grant approvals on a timely basis or may revoke previously granted approvals. Any delay in obtaining, or failure to obtain, approvals could adversely affect the marketing of our products and our ability to generate product revenue.

The process of obtaining FDA and other required regulatory approvals is lengthy and expensive. The time required for FDA and other clearances or approvals is uncertain and typically takes a number of years, depending on the complexity and novelty of the product. We have only limited experience in filing and prosecuting applications necessary to gain regulatory approvals.

Our analysis of data obtained from preclinical and clinical activities is subject to confirmation and interpretation by regulatory authorities which could delay, limit or prevent regulatory approval. Any regulatory approval to market a product may be subject to limitations on the indicated uses for which we may market the product. These limitations may limit the size of the market for the product.

We also are subject to numerous foreign regulatory requirements governing the design and conduct of the clinical trials and the manufacturing and marketing of our future products. The approval procedure varies among countries. The time required to obtain foreign approvals often differs from that required to obtain FDA approvals. Moreover, approval by the FDA does not ensure approval by regulatory authorities in other countries.

Even if we obtain marketing approval, our products will be subject to ongoing regulatory oversight which may affect the success of our products

Any regulatory approvals that we receive for a product may be subject to limitations on the indicated uses for which the product may be marketed or contain requirements for costly post-marketing follow-up studies. After we obtain marketing approval for any product, the manufacturer and the manufacturing facilities for that product will be subject to continual review and periodic inspections by the FDA and other regulatory authorities. The subsequent discovery of previously unknown problems with the product, such as the presence of PERV, or with the manufacturer or facility, may result in restrictions on the product or manufacturer, including withdrawal of the product from the market.

If we fail to comply with applicable regulatory requirements, we may be subject to fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions, and criminal prosecution.

Risks Relating to Financing Our Business

We have incurred substantial losses, we expect to continue to incur losses and we may never achieve profitability

We have incurred losses in each year since our founding in 1989. At December 31, 2001, we had an accumulated deficit of \$52.4 million. We expect to incur substantial operating losses for the foreseeable future. We have no material sources of revenue from product sales or license fees. We anticipate that it will be a number of years, if ever, before we develop significant revenue sources or become profitable, even if we are able to commercialize products.

Edgar Filing: DIACRIN INC /DE/ - Form 10-K

We expect to increase our spending significantly as we continue to expand our research and development programs, expand our clinical trials, apply for regulatory approvals and begin commercialization activities. In particular, we may devote significant economic resources to funding our joint venture with Genzyme and to its product development plans. Under the joint venture agreement, we are currently required to provide 25% of the funding required for the development and commercialization of NeuroCell-PD and NeuroCell-HD and in the future will be required to provide 50% of the required funding.

We may require additional financing, which may be difficult to obtain and may dilute your ownership interest

We will require substantial funds to conduct research and development, including clinical trials of our product candidates, and to manufacture and market any products that are approved for commercial sale. Our future capital requirements will depend on many factors, including the following:

- the analysis of the data from the Phase 2 clinical trial of NeuroCell-PD which could result in the termination of our joint venture with Genzyme;
- continued progress in our research and development programs, as well as the magnitude of these programs;
- the resources required to successfully complete our clinical trials;
- the time and costs involved in obtaining regulatory approvals;
- the cost of manufacturing and commercialization activities;
- the cost of any additional facilities requirements;
- the timing, receipt and amount of milestone and other payments from future collaborative partners;
- the timing, receipt and amount of sales and royalties from our potential products in the market; and
- the costs involved in preparing, filing, prosecuting, maintaining and enforcing patent claims and other patent-related costs, including litigation costs and the costs of obtaining any required licenses to technologies.

We may seek additional funding through collaborative arrangements and public or private financings. Additional financing may not be available to us on acceptable terms or at all.

If we raise additional funds by issuing equity securities further dilution to our then existing stockholders may result. In addition, the terms of the financing may adversely affect the holdings or the rights of our stockholders. If we are unable to obtain funding on a timely basis, we may be required to significantly curtail one or more of our research or development programs.

We also could be required to seek funds through arrangements with collaborative partners or others that may require us to relinquish rights to certain of our technologies, product candidates, or products which we would otherwise pursue independently.

Risks Relating to Intellectual Property

We may not be able to obtain patent protection for our discoveries and we may infringe patent rights of others

Edgar Filing: DIACRIN INC /DE/ - Form 10-K

The patent positions of pharmaceutical and biotechnology companies, including us, are generally uncertain and involve complex legal, scientific and factual issues.

Our success depends significantly on our ability to:

- obtain patents;
- protect trade secrets;
- operate without infringing upon the proprietary rights of others; and
- prevent others from infringing on our proprietary rights.

Patents may not issue from any patent applications that we own or license. If patents do issue, the claims allowed may not be sufficiently broad to protect our technology. In addition, issued patents that we own or license may be challenged, invalidated or circumvented. Our patents also may not afford us protection against competitors with similar technology. Because patent applications in the United States may be maintained in secrecy until patents issue, others may have filed or maintained patent applications for technology used by us or covered by our pending patent applications without our being aware of these applications.

We may not hold proprietary rights to some patents related to our proposed products. In some cases, others may own or control these patents. As a result, we or our collaborative partners may be required to obtain licenses under third-party patents to market some of our proposed products. If licenses are not available to us on acceptable terms, we will not be able to market these affected products.

If we are not able to keep our trade secrets confidential, our technology and information may be used by others to compete against us

We rely significantly upon unpatented proprietary technology, information, processes and know how. We seek to protect this information by confidentiality agreements with our employees, consultants and other third-party contractors as well as through other security measures. These confidentiality agreements may be breached, and we may not have adequate remedies for any such breach. In addition, our trade secrets may otherwise become known or be independently developed by competitors.

We may become involved in expensive patent litigation or other intellectual property proceedings which could result in liability for damages or stop our development and commercialization efforts

There has been substantial litigation and other proceedings regarding the complex patent and other intellectual property rights in the pharmaceutical and biotechnology industries. We may become a party to patent litigation or other proceedings regarding intellectual property rights.

The types of situations in which we may become involved in patent litigation or other intellectual property proceedings include:

- we may initiate litigation or other proceedings against third parties to enforce our patent rights;
- we may initiate litigation or other proceedings against third parties to seek to invalidate the patents held by these third parties or to obtain a judgment that our products or services do not infringe the third parties' patents;

Edgar Filing: DIACRIN INC /DE/ - Form 10-K

- if our competitors file patent applications that claim technology also claimed by us, we may participate in interference or opposition proceedings to determine the priority of invention; and
- if third parties initiate litigation claiming that our processes or products infringe their patent or other intellectual property rights, we will need to defend against such claims.

The cost to us of any patent litigation or other proceeding, even if resolved in our favor, could be substantial. Some of our competitors may be able to sustain the cost of such litigation or proceedings more effectively than we can because of their substantially greater financial resources. If a patent litigation or other intellectual property proceeding is resolved unfavorably to us, we may be enjoined from manufacturing or selling our products and services without a license from the other party and be held liable for significant damages. We may not be able to obtain any required license on commercially acceptable terms or at all.

Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace. Patent litigation and other proceedings may also absorb significant management time.

If we breach any of the agreements under which we license technology from others we could lose license rights that are important to our business

We are a party to technology in-licenses that are important to our business and expect to enter into additional licenses in the future. In particular, our immunomodulation technology and some of our product candidates are covered by patents licensed from Massachusetts General Hospital. These licenses impose commercialization, sublicensing, royalty, insurance and other obligations on us. If we fail to comply with these requirements, the licensor will have the right to terminate the license.

Risks Relating to Product Manufacturing, Marketing and Sales

Since we have no sales and marketing experience or infrastructure, we must rely on third parties

We have no sales, marketing and distribution experience or infrastructure. We plan to rely significantly on sales, marketing and distribution arrangements with third parties for the products that we are developing. For example, under our joint venture agreement, we have granted to Genzyme (on behalf of the joint venture) exclusive worldwide marketing rights to NeuroCell-PD and NeuroCell-HD. We may have limited or no control over the sales, marketing and distribution activities of Genzyme, the joint venture or any future collaborative partners. Our future revenues will be materially dependent upon the success of the efforts of these third parties.

If in the future we determine to perform sales, marketing and distribution functions ourselves, we would face a number of additional risks, including:

- we may not be able to attract and build a significant marketing or sales force;
- the cost of establishing a marketing or sales force may not be justifiable in light of any product revenues; and
- our direct sales and marketing efforts may not be successful.

Delays in obtaining regulatory approval of our manufacturing facility and

Edgar Filing: DIACRIN INC /DE/ - Form 10-K

disruptions in our manufacturing process may delay or disrupt our commercialization efforts

Before we can begin commercially manufacturing our product candidates, we must obtain regulatory approval of our manufacturing facility and process. Manufacturing of our product candidates must comply with cGMP, and foreign regulatory requirements. The cGMP requirements govern quality control and documentation policies and procedures. In complying with cGMP and foreign regulatory requirements, we will be obligated to expend time, money and effort on production, recordkeeping and quality control to ensure that our product candidates meet applicable specifications and other requirements. If we fail to comply with these requirements, we would be subject to possible regulatory action and may be limited in the jurisdictions in which we are permitted to sell our product candidates.

We are the only manufacturers of our product candidates. For the next several years, we expect that we will conduct all of our manufacturing in our facility in Charlestown, Massachusetts. If this facility or the equipment in this facility is significantly damaged or destroyed, we will not be able to replace quickly or inexpensively our manufacturing capacity.

We have no experience manufacturing our product candidates in the volumes that will be necessary to support large clinical trials or commercial sales. Our present manufacturing process may not meet our initial expectations as to scheduling, reproducibility, yield, purity, cost, potency or quality.

The manufacture of our products would be delayed by disruptions in our supply of porcine tissue

The manufacture of our products requires the continuous availability of porcine tissue harvested from pigs tested to be free of infectious agents and quarantined in a qualified animal facility. Our main sources of these facilities and services are Tufts University School of Veterinary Medicine and PharmServices, Inc., a division of Charles River Laboratories, Inc. A disease epidemic or other catastrophe in either of these facilities could destroy all or a portion of our pig supply, which would interrupt or significantly delay the research, development and commercialization of our products.

Risks Related to Ongoing Operations

If we fail to obtain an adequate level of reimbursement for our future products by third party payors, there may be no commercially viable markets for our products

Our products may be more expensive than conventional treatments because they involve the surgical transplantation of living cells. The availability of reimbursement by governmental and other third-party payors affects the market for any pharmaceutical product. These third-party payors continually attempt to contain or reduce the costs of health care by challenging the prices charged for medical products. In some foreign countries, particularly the countries of the European Union, the pricing of prescription pharmaceuticals is subject to governmental control. We may not be able to sell our products profitably if reimbursement is unavailable or limited in scope or amount.

In both the United States and some foreign jurisdictions, there have been a number of legislative and regulatory proposals to change the health care system. Further proposals are likely. The potential for adoption of these proposals may affect our ability to raise capital, obtain additional collaborative partners and market our products.

If we obtain marketing approval for our products, we expect to experience pricing pressure due to the trend toward managed health care, the increasing

Edgar Filing: DIACRIN INC /DE/ - Form 10-K

influence of health maintenance organizations and additional legislative proposals.

We could be exposed to significant liability claims if we are unable to obtain insurance at acceptable costs or otherwise to protect us against potential product liability claims

We may be subjected to product liability claims that are inherent in the testing, manufacturing, marketing and sale of human health care products. These claims could expose us to significant liabilities that could prevent or interfere with the development or commercialization of our products. Product liability claims could require us to spend significant time and money in litigation or to pay significant damages. Product liability insurance is generally expensive for biopharmaceutical companies such as ours. Although we maintain limited product liability insurance coverage for the clinical trials of our products, it is possible that we will not be able to obtain further product liability insurance on acceptable terms, if at all, and that our present insurance levels and any insurance we subsequently obtain will not provide adequate coverage against all potential claims.

Our growth could be limited if we are unable to attract and retain key personnel and consultants

Our success depends substantially on our ability to attract and retain qualified scientific and technical personnel for the research and development activities we conduct or sponsor. If we lose one or more of the members of our senior management or other key employees or consultants, our business and operating results could be seriously harmed.

Our anticipated growth and expansion into areas and activities requiring additional expertise, such as regulatory compliance, manufacturing and marketing, will require the addition of new management personnel. The pool of personnel with the skills that we require is limited. Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate such additional personnel.

Risks Relating to our Common Stock

Our officers and directors may be able to control the outcome of most corporate actions requiring stockholder approval

Our directors and officers and entities with which they are affiliated control approximately 40% of our outstanding common stock. Due to this concentration of ownership, this group may be able to prevail on all matters requiring a stockholder vote, including:

- the election of directors;
- the amendment of our organizational documents; or
- the approval of a merger, sale of assets or other major corporate transaction.

Our stock price could be volatile, which could cause you to lose part or all of your investment

The market price of our common stock, like that of the common stock of many other development stage biotechnology companies, may be highly volatile. In addition, the stock market has experienced extreme price and volume fluctuations. This volatility has significantly affected the market prices of securities of many biotechnology and pharmaceutical companies for reasons frequently unrelated to or disproportionate to the operating performance of the

Edgar Filing: DIACRIN INC /DE/ - Form 10-K

specific companies. These broad market fluctuations may adversely affect the market price of our common stock. Prices for our common stock will be determined in the market place and may be influenced by many factors, including variations in our financial results and investors' perceptions of us, changes in recommendations by securities analysts as well as their perceptions of general economic, industry and market conditions.

We have antitakeover defenses that could delay or prevent an acquisition and could adversely affect the price of our common stock

Provisions of our certificate of incorporation, our bylaws, and Delaware law may have the effect of deterring unsolicited takeovers or delaying or preventing changes in control of our management, including transactions in which our stockholders might otherwise receive a premium for their shares over then current market prices. In addition, these provisions may limit the ability of stockholders to approve transactions that they may deem to be in their best interest.

Our certificate of incorporation permits our board of directors to issue preferred stock without shareholder approval upon such terms as the board of directors may determine. The rights of the holders of our common stock will be subject to, and may be adversely affected by, the rights of the holders of any preferred stock that may be issued in the future. The issuance of preferred stock, while providing desirable flexibility in connection with possible acquisitions and other corporate purposes, could have the effect of making it more difficult for a third party to acquire, or of discouraging a third party from acquiring, a majority of our outstanding common stock. The issuance of a substantial number of preferred shares could adversely affect the price of our common stock.

Item 7A. Quantitative and Qualitative Disclosures About Market Risk

We own financial instruments that are sensitive to market risks as part of our investment portfolio. The investment portfolio is used to preserve our capital until it is required to fund operations, including our research and development activities. None of these market-risk sensitive instruments are held for trading purposes. We do not own derivative financial instruments in our investment portfolio. Our investment portfolio contains instruments that are subject to the risk of a decline in interest rates. For example, if the interest rate on our interest bearing investments were to change 1%, investment income would have hypothetically increased or decreased by approximately \$520,000 in 2001. This hypothetical analysis does not take into consideration the effects of the economic conditions that would give rise to such an interest rate change or our response to such hypothetical conditions.

Our investment portfolio includes investment grade debt instruments. These bonds are subject to interest rate risk, and could decline in value if interest rates fluctuate. Due to the short duration and conservative nature of these instruments, we do not believe that it has a material exposure to interest rate risk.

Item 8. Financial Statements

The financial statements required to be filed hereunder are filed as an exhibit hereto, are listed under item 14(a)(1) and are incorporated herein by reference.

Item 9. Changes in and Disagreements on Accounting and Financial Disclosure

There have been no disagreements on accounting and financial disclosure matters.

Edgar Filing: DIACRIN INC /DE/ - Form 10-K

PART III

Item 10. Directors and Executive Officers of the Registrant

Information regarding our executive officers and directors is furnished in Part I of this Annual Report on Form 10-K under the heading "Executive Officers of the Registrant."

Section 16(a) Beneficial Ownership Reporting Compliance

Section 16(a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), requires our directors, executive officers and persons who own more than ten percent of a registered class of our equity securities to file with the Securities and Exchange Commission initial reports of ownership and reports of changes in ownership of common stock and other equity securities. Officers, directors and greater than ten percent beneficial owners are required to furnish us with copies of all Section 16(a) forms that they file.

Based solely on our review of the copies of such reports received or written representations that no other reports were required, we believe that, except as follows, during the fiscal year ended December 31, 2001, our officers, directors and ten-percent stockholders complied with all Section 16(a) filing requirements applicable to such individuals. A Form 5, Annual Statement of Changes in Beneficial Ownership, for Mr. Littlechild reporting a stock option grant was inadvertently filed late.

Item 11. Executive Compensation

Summary Compensation Table. The following table sets forth certain information with respect to the annual and long-term compensation for each of the last three fiscal years of each of our executive officers:

Name and Principal Position	Year	Annual Compensation		Long-Term Compensation Awards Securities Underlying Options (#)	All Other Compensation (3)
		Salary (\$) (1)	Bonus (\$) (2)		
Thomas H. Fraser President and Chief Executive Officer	2001	\$ 275,000	\$ 137,500	-	\$5,250
	2000	270,000	25,000	25,000	2,625
	1999	260,000	40,000	25,000	-
E. Michael Egan Chief Operating Officer	2001	\$ 220,000	\$ 110,000	-	\$5,250
	2000	200,000	20,000	20,000	2,625
	1999	190,000	30,000	20,000	-
Kevin Kerrigan Controller	2001	\$ 93,500	\$ 46,750	-	\$2,805
	2000	85,000	8,000	10,000	1,275
	1999	75,000	8,000	10,000	-

Edgar Filing: DIACRIN INC /DE/ - Form 10-K

- (1) Amounts shown include cash compensation earned and received by the Named Officers as well as amounts earned but deferred at the election of these officers to our 401(k) Plan.
- (2) Amounts in this column represent bonuses paid or accrued under a retention or bonus plan.
- (3) Represents matching contributions under our 401(k) Plan.

Aggregated Option Exercises and Year-End Option Table. The following table sets forth certain information regarding aggregate option exercises during the fiscal year ended December 31, 2001 and the number and value of unexercised stock options held as of December 31, 2001 by the Named Officers:

Name	Shares Acquired on Exercise (#)	Value Realized (\$)(1)	Number of Securities Underlying Unexercised Options at Fiscal Year-End(#)	Value of Unexercised the-Money Options at Fiscal Year-End(\$)(2)
			Exercisable/Unexercisable	Exercisable/Unexercisable
Thomas H. Fraser	22,500	\$13,500	162,500/37,500	\$11,250/ -
E. Michael Egan	-	-	182,495/30,000	\$44,373/ -
Kevin Kerrigan	-	-	17,000/15,000	- / -

- (1) Represents the difference between the exercise price and the value of our common stock on the date of exercise.
- (2) Based on the value of our common stock on December 31, 2001 (\$1.85 per share), the last trading day of 2001, less the applicable option exercise price.

Director Compensation

Dr. Horovitz receives \$2,000 plus expenses per board meeting he attends plus an additional \$4,000 annually for consulting work performed on our behalf. No other directors receive any cash compensation for services on the board of directors.

On June 11, 2001, all non-employee directors were granted an option to purchase 6,000 shares of common stock under our 1997 Stock Option Plan at an exercise price of \$2.00 per share. The options may be exercised on a cumulative basis as to 25% of the shares on the first anniversary of the date of grant and an additional 25% at the end of each one-year period thereafter.

Employment Agreements

We entered into a letter agreement with Dr. Fraser dated February 6, 1990, providing for an annual salary plus bonus as determined by our board of directors. We have agreed with Dr. Fraser to continue to pay his then current salary for a period of six months if we terminate his employment without cause. Dr. Fraser has also agreed not to compete with us for one year following termination of his employment. At our election, this non-competition provision can be extended for an additional two-year period upon the payment of additional

Edgar Filing: DIACRIN INC /DE/ - Form 10-K

consideration.

Compensation Committee Interlocks and Insider Participation

Mr. Termeer serves on our Compensation Committee. In September 1996, we formed a joint venture with Genzyme Corporation to develop and commercialize two product candidates. Under the terms of the joint venture agreement which became effective on October 1, 1996, Genzyme agreed to provide 100% of the first \$10 million in funding and 75% of the following \$40 million in funding for the development and commercialization of the two products. All costs incurred in excess of \$50 million are to be shared equally between us and Genzyme in accordance with the terms of the agreement. Any profits of the joint venture will be shared equally by the two parties. Mr. Termeer, a member of our board of directors, is President, Chief Executive Officer and Chairman of the Board of Genzyme. We have recorded approximately \$15.2 million in revenue from the joint venture since it commenced, \$737,290 of which the Company recognized during 2001.

Item 12. Security Ownership of Certain Beneficial Owners and Management

The following table sets forth the beneficial ownership of our common stock as of February 28, 2002 by:

- each person who is known to beneficially own more than 5% of our common stock;
- each of our directors;
- each of our executive officers; and
- all of our executive officers and directors as a group.

Unless otherwise noted, each person or group has sole voting and investment power of the shares listed. The inclusion of any shares listed below as beneficially owned does not constitute an admission of beneficial ownership of those shares.

The "Options" column reflects shares of our common stock subject to options which are exercisable within 60 days after February 28, 2002. The shares of our common stock which are subject to options are deemed to be outstanding for the purpose of computing the percentage of ownership of the person holding such options, but are not deemed to be outstanding for computing the percentage of ownership of any other person. As of February 28, 2002, there were 17,937,204 shares of our common stock outstanding.

Name and Address -----	Number of Shares Beneficially Owned		Percentage of Common Stock Outstanding
	Shares -----	Options -----	
HealthCare Ventures II, L.P. (1).....	3,196,385	--	17.8%
HealthCare Ventures III, L.P. (1).....	994,078	--	5.5
HealthCare Ventures IV, L.P. (1).....	291,922	--	1.6

Edgar Filing: DIACRIN INC /DE/ - Form 10-K

State of Wisconsin Investment Board (2).....	2,658,200	--	14.8
Rho Management Trust II (3).....	1,592,887	--	8.9
Hudson Trust (4).....	1,342,680	--	7.5
Thomas H. Fraser, Ph.D.....	505,988	162,500	3.7
Zola P. Horovitz, Ph.D.	4,000	19,500	*
John W. Littlechild (1).....	4,482,385	19,500	25.1
Stelios Papadopoulos, Ph.D.....	200,000	19,500	1.2
Joshua Ruch (5).....	1,759,587	19,500	9.9
Henri A. Termeer.....	7,750	49,000	*
E. Michael Egan.....	4,169	182,495	1.0
Kevin Kerrigan.....	--	17,000	*
All directors and executive officers as a group (8 persons)	6,963,879	488,995	40.4

* Less than 1.0%

- (1) John W. Littlechild is a general partner of HealthCare Partners II, L.P. ("HCPII"), HealthCare Partners III, L.P. ("HCPIII") and HealthCare Partners IV, L.P. ("HCPIV"), the general partner of HealthCare Ventures II, L.P. ("HCVII"), HealthCare Ventures III, L.P. ("HCVIII") and HealthCare Ventures IV, L.P. ("HCVIV"), respectively. Mr. Littlechild, together with James H. Cavanaugh, Harold R. Werner and William Crouse, the other general partners of HCPII, HCPIII and HCPIV, share voting and investment control with respect to shares owned by HCVII, HCVIII and HCVIV, respectively. Mr. Littlechild does not own any shares of our capital stock in his individual capacity. The address of HealthCare Ventures II, III and IV, L.P. is 44 Nassau Street, Princeton, New Jersey 08542.
- (2) The address of the State of Wisconsin Investment Board is P.O. Box 7842, Madison, Wisconsin 53707.
- (3) Rho Capital Partners, Inc. ("Rho") may be deemed the beneficial owner of these shares pursuant to an investment advisory agreement that confers voting and investment control over such shares to Rho. The address of Rho Management Trust II is c/o Rho Capital Partners, Inc., 152 West 57th Street, New York, New York 10019.
- (4) The address of Hudson Trust is c/o Summit Asset Management Co., Inc., 47 Hulfish Street, Suite 420, Princeton, New Jersey 08542.
- (5) Mr. Ruch is a controlling person of Rho and as such may be deemed the beneficial owner of the shares held by Rho Management Trust II. In addition, Mr. Ruch exercises investment and voting authority over 166,700 shares directly for his own account, for the account of family members or for the account of other clients of Rho or its affiliates.

Item 13. Certain Relationships and Related Transactions

HCVII, HCVIII and HCVIV owned 17.8%, 5.5% and 1.6% of our outstanding capital stock as of February 28, 2002, respectively. HCVII, HCVIII and HCVIV are limited partnerships which were formed to provide capital to companies in the health care fields. HCPII, HCPIII and HCPIV are limited partnerships which serve as general partner of HCVII, HCVIII and HCVIV, respectively. John Littlechild, a member of our board of directors, is a general partner of HCPII, HCPIII and HCPIV and Vice Chairman of Healthcare Ventures LLC, the management company for HCVII, HCVIII and HCVIV. Mr. Littlechild is an officer of HealthCare Ventures LLC. See "Security Ownership of Certain Beneficial Owners and Management."

Rho Management Trust II, which owned 8.9% of our outstanding capital

Edgar Filing: DIACRIN INC /DE/ - Form 10-K

stock as of February 28, 2002, also holds approximately 18.9% and 54.3% of the outstanding limited partnership interests of HCVII and HCVIV, respectively. An affiliate of Rho is also a limited partner of HCPH, HCPHII and HCPHIII. Joshua Ruch, a member of our board of directors, is a controlling person of Rho. See "Security Ownership of Certain Beneficial Owners and Management."

Hudson Trust, which owned 7.5% of our outstanding capital stock as of February 28, 2002, also holds approximately 6.0% and 11.9% of the outstanding limited partnership interests of HCVII and HCVIV, respectively. Hudson is also a limited partner of HCPH. See "Security Ownership of Certain Beneficial Owners and Management."

See "Executive Compensation - Compensation Committee Interlocks and Insider Participation."

PART IV

Item 14. Exhibits, Financial Statements and Reports on Form 8-K

(a) (1) Index to Financial Statements

The following Financial Statements are included in this Annual Report on Form 10-K.

Financial Statements:	Page
(a.) Diacrin, Inc.	
1. Report of Independent Public Accountants	F-1
2. Balance Sheets as of December 31, 2000 and 2001	F-2
3. Statements of Operations for each of the three years in the period ended December 31, 2001	F-3
4. Statements of Stockholders' Equity (Deficit) for each of the three years in the period ended December 31, 2001	F-4
5. Statements of Cash Flow for each of the three years in the period ended December 31, 2001	F-5
6. Notes to Financial Statements	F-6
(b.) Diacrin/Genzyme LLC (A Development Stage Enterprise)	
1. Report of Independent Public Accountants	F-18
2. Balance Sheets as of December 31, 2000 and 2001	F-19
3. Statements of Operations for the years ended December 31, 2000 and 2001 and for the period from October 1, 1996 (date of inception) to December 31, 2001	F-20

Edgar Filing: DIACRIN INC /DE/ - Form 10-K

4.	Statements of Cash Flows for the years ended December 31, 2000 and 2001 and for the period from October 1, 1996 (date of inception) to December 31, 2001	F-21
5.	Statements of Change in Venturers' Capital (Deficit) for the period from October 1, 1996 (date of inception) to December 31, 2001	F-22
6.	Notes to Financial Statements	F-23

(2) Exhibits

The following is a list of exhibits filed as part of this Annual Report on Form 10-K:

Exhibit No. -----	Title -----	Page ----
3.1	- Amended and Restated Certificate of Incorporation of Diacrin as amended to date	(5)
3.2	- Amended and Restated By-laws of Diacrin	(4)
+10.1	- Employment Agreement dated February 6, 1990 by and between Diacrin and Dr. Thomas H. Fraser	(2)
10.2	- Rights Agreement dated July 29, 1991 by and among Diacrin and the holders of the preferred stock as amended on September 27, 1991	(2)
10.2(a)	- Consent and Agreement to Amend dated April 26, 1995 by and among Diacrin and certain investors named therein	(1)
10.2(b)	- Consent and Agreement to Amend dated as of January 4, 1996 by and among Diacrin and certain investors named therein	(4)
+10.3	- 1990 Stock Option Plan, as amended	(3)
10.4	- Sublease dated January 24, 1991 by and among Diacrin and Building 79 Associated Limited Partnership and Building 96 Associates Limited Partnership	(2)
+10.5	- 1994 Directors' Stock Option Plan, as amended	(7)
10.6	- Registration Rights Agreements dated May 31, 1995 by and among Diacrin and the investors listed on Schedules I and II attached thereto	(1)
10.6(a)	- Amendment No. 1 to Registration Rights Agreement dated as of January 4, 1996 by and among Diacrin and certain investors named therein	(4)
10.7	- Collaboration Agreement among Diacrin, Inc., Genzyme Corporation and Diacrin/Genzyme LLC dated as of October 1, 1996	(6)
10.8	- Operating Agreement of Diacrin/Genzyme LLC	(6)

Edgar Filing: DIACRIN INC /DE/ - Form 10-K

Exhibit No. -----	Title -----	Page -----
+10.9	- 1997 Stock Option Plan	(8)
10.10	- \$650,000 Promissory Note dated November 25, 1997 made by Diacrin to the order of Fleet National Bank	(9)
10.10(a)	- Letter Agreement dated November 25, 1997 by and between Diacrin and Fleet National Bank	(9)
21	- Subsidiaries	*
23.1	- Consent of Arthur Andersen LLP	*
23.2	- Consent of PricewaterhouseCoopers LLP	*
99	- Letter to Commission Pursuant to Temporary Note 3T	*

* Filed herewith

(1) Filed as an exhibit to our Quarterly Report on Form 10-Q (File No. 0-20139) for the quarter ended June 30, 1995 and incorporated herein by reference.

(2) Filed as an exhibit to our Form 10, as amended (File No. 0-20139), on April 29, 1992, and incorporated herein by reference.

(3) Filed as an exhibit to our Quarterly Report on Form 10-Q (File No. 0-20139) for the quarter ended September 30, 1994 and incorporated herein by reference.

(4) Filed as an exhibit to our Registration Statement on Form S-2, as amended (Registration No. 33-80773) on December 22, 1995, and incorporated herein by reference.

(5) Filed as an exhibit to our Annual Report on Form 10-K (File No. 0-20139) for the fiscal year ended December 31, 1995 and incorporated herein by reference.

(6) Filed as an exhibit to our Quarterly Report on Form 10-Q, as amended on Form 10-Q/A (File No. 0-20139) for the quarter ended September 30, 1996 and incorporated herein by reference.

(7) Filed as an exhibit to our Annual Report on Form 10-K (File No. 0-20139) for the fiscal year ended December 31, 1996 and incorporated herein by reference.

(8) Filed as an exhibit to our Quarterly Report on Form 10-Q (File No. 0-20139) for the quarter ended June 30, 1997 and incorporated herein by reference.

(9) Filed as an exhibit to our Annual Report on Form 10-K (File No. 0-20139) for the fiscal year ended December 31, 1997 and incorporated herein by reference.

Edgar Filing: DIACRIN INC /DE/ - Form 10-K

+ Management contract or compensatory plan or arrangement filed as an exhibit to this Form pursuant to Items 14(a) and 14(c) of Form 10-K.

(b) Reports on Form 8-K.

We did not file any current reports on Form 8-K during the last quarter of the period covered by this report.

(c) Description of Exhibits.

See Item 14 (a)

(d) Description of Financial Statement Schedules.

None.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Form 10-K to be signed on its behalf by the undersigned, thereunto duly authorized.

DIACRIN, INC.

By: /s/ Thomas H. Fraser

Thomas H. Fraser
President and Chief Executive Officer

Date: March 28, 2002

Pursuant to the requirement of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated:

Table with 3 columns: Signature, Date, Title. Rows include Thomas H. Fraser (President, Chief Executive Officer and Director), Kevin Kerrigan (Controller), and Zola P. Horovitz (Director).

Edgar Filing: DIACRIN INC /DE/ - Form 10-K

John W. Littlechild

/s/ Stelios Papadopoulos March 28, 2002 Director

Stelios Papadopoulos

/s/ Henri A. Termeer March 28, 2002 Director

Henri A. Termeer

/s/ Joshua Ruch March 28, 2002 Director

Joshua Ruch

Report of Independent Public Accountants

To the Board of Directors of
Diacrin, Inc.:

We have audited the accompanying balance sheets of Diacrin, Inc. (a Delaware corporation) as of December 31, 2000 and 2001 and the related statements of operations, stockholders' equity and cash flows for each of the three years in the period ended December 31, 2001. These financial statements are the responsibility of Diacrin, Inc.'s management. Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our audits in accordance with auditing standards generally accepted in the United States. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Diacrin, Inc. as of December 31, 2000 and 2001 and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2001, in conformity with accounting principles generally accepted in the United States.

/s/ Arthur Andersen LLP

Boston, Massachusetts
February 21, 2002

Edgar Filing: DIACRIN INC /DE/ - Form 10-K

DIACRIN, INC.
Balance Sheets

	At December 31,	
	2000	2001
	----	----
ASSETS		
Current assets:		
Cash and cash equivalents	\$ 11,143,116	\$ 8,534,426
Short-term investments	22,485,675	33,410,736
Interest receivable and other current assets	780,406	668,020
	-----	-----
Total current assets	34,409,197	42,613,182
	-----	-----
Property and equipment, at cost:		
Laboratory and manufacturing equipment	1,655,064	1,660,963
Furniture and office equipment	320,106	324,913
Leasehold improvements	77,529	77,529
	-----	-----
	2,052,699	2,063,405
Less - Accumulated depreciation and amortization	1,651,618	1,861,110
	-----	-----
	401,081	202,295
	-----	-----
Long-term investments	20,977,940	7,782,035
Investment in joint venture	4,785	83,984
	-----	-----
Total other assets	20,982,725	7,866,019
	-----	-----
Total assets	\$ 55,793,003	\$ 50,681,496
	=====	=====
LIABILITIES AND STOCKHOLDERS' EQUITY		
Current liabilities:		
Current portion of long-term debt	\$ 130,000	\$ 119,167
Accounts payable	109,307	117,663
Accrued expenses	1,323,786	1,269,278
Deferred revenue from joint venture	344,468	29,238
	-----	-----
Total current liabilities	1,907,561	1,535,346
Long-term debt, net of current portion	119,167	-
Commitments (Notes 4 and 10)		
Stockholders' equity:		
Preferred stock, \$0.01 par value; authorized--5,000,000 shares; none issued and outstanding	-	-
Common stock, \$0.01 par value; authorized--30,000,000 shares; issued and outstanding--17,914,704 and 17,937,204 shares at December 31, 2000 and 2001, respectively	179,147	179,372
Additional paid-in capital	101,373,922	101,401,822

Edgar Filing: DIACRIN INC /DE/ - Form 10-K

Accumulated deficit	(47,786,794)	(52,435,044)
	-----	-----
Total stockholders' equity	53,766,275	49,146,150
	-----	-----
Total liabilities and stockholders' equity	\$ 55,793,003	\$ 50,681,496
	=====	=====

The accompanying notes are an integral part of these financial statements.

F-2

DIACRIN, INC.
Statements of Operations

	Year Ended December 31,		
	1999	2000	2001
	----	----	----
REVENUES:			
Research and development	\$ 2,970,846	\$ 2,081,795	\$ 737,290
Investment income	1,323,520	3,124,929	3,149,543
	-----	-----	-----
Total revenues	4,294,366	5,206,724	3,886,833
	-----	-----	-----
OPERATING EXPENSES:			
Research and development	5,921,141	5,996,550	6,350,190
General and administrative	1,398,151	1,348,072	1,624,470
Interest expense	47,318	29,898	13,861
	-----	-----	-----
Total operating expenses	7,366,610	7,374,520	7,988,521
	-----	-----	-----
EQUITY IN OPERATIONS OF JOINT VENTURE	(1,688,071)	(1,368,945)	(546,562)
	-----	-----	-----
NET LOSS	\$ (4,760,315)	\$ (3,536,741)	\$ (4,648,250)
	=====	=====	=====
NET LOSS PER COMMON SHARE:			
Basic and diluted	\$ (.33)	\$ (.21)	\$ (.26)
	=====	=====	=====
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:			
Basic and diluted	14,364,154	17,073,194	17,914,889
	=====	=====	=====

Edgar Filing: DIACRIN INC /DE/ - Form 10-K

The accompanying notes are an integral part of
these financial statements.

F-3

DIACRIN, INC. Statements of Stockholders' Equity

	Common Stock		Additional Paid-In Capital	Accumulated Deficit	Sto
	Number of Shares	\$.01 Par Value			
BALANCE, December 31, 1998	14,327,218	143,272	64,191,075	(39,489,738)	24
Exercise of stock options	58,965	590	59,666	-	
Net loss	-	-	-	(4,760,315)	(4
BALANCE, December 31, 1999	14,386,183	143,862	64,250,741	(44,250,053)	20
Proceeds from public offering of common stock, net of \$2,765,500 financing costs	3,450,000	34,500	36,875,000	-	36
Exercise of stock options and warrants	78,521	785	248,181	-	
Net loss	-	-	-	(3,536,741)	(3
BALANCE, December 31, 2000	17,914,704	179,147	101,373,922	(47,786,794)	53
Exercise of stock options	22,500	225	27,900	-	
Net loss	-	-	-	(4,648,250)	(4
BALANCE, December 31, 2001	17,937,204	179,372	101,401,822	(52,435,044)	49

The accompanying notes are an integral part of
these financial statements.

F-4

Edgar Filing: DIACRIN INC /DE/ - Form 10-K

DIACRIN, INC.
Statements of Cash Flows

	Year Ended December 31,		
	1999	2000	2001
	----	----	----
CASH FLOWS FROM OPERATING ACTIVITIES:			
Net loss	\$ (4,760,315)	\$ (3,536,741)	\$ (4,6
Adjustments to reconcile net loss to net cash used in operating activities-			
Depreciation and amortization	237,976	213,969	2
Equity in operations of joint venture	1,688,071	1,368,945	5
Changes in current assets and liabilities-			
Interest receivable and other current assets	65,048	(451,041)	1
Accounts payable	(129,234)	(29,461)	
Accrued expenses	(126,762)	55,866	1
Deferred revenue from joint venture	99,872	(94,259)	(3
	-----	-----	-----
Net cash used in operating activities	(2,925,344)	(2,472,722)	(3,9
	-----	-----	-----
CASH FLOWS FROM INVESTING ACTIVITIES:			
Decrease (increase) in short-term investments	2,088,140	(5,903,423)	(10,9
Purchases of property and equipment, net	(26,019)	(102,510)	(
(Increase) decrease in long-term investments	(39,074)	(18,333,856)	13,1
Investment in joint venture	(2,669,384)	(1,947,422)	(1,0
Return of capital for services provided on behalf of joint venture	990,282	693,932	2
	-----	-----	-----
Net cash provided by (used in) investing activities	343,945	(25,593,279)	1,4
	-----	-----	-----
CASH FLOWS FROM FINANCING ACTIVITIES:			
Net proceeds from sale of common stock	-	36,909,500	
Net proceeds from the exercise of stock options and warrants	60,256	248,966	
Principal payments on long-term debt	(279,910)	(143,350)	(1
	-----	-----	-----
Net cash (used in) provided by financing	(219,654)	37,015,116	(1
	-----	-----	-----
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS	(2,801,053)	8,949,115	(2,6
CASH AND CASH EQUIVALENTS, beginning of year	4,995,054	2,194,001	11,1
	-----	-----	-----
CASH AND CASH EQUIVALENTS, end of year	\$ 2,194,001	\$11,143,116	\$ 8,5
	=====	=====	=====
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:			
Cash paid for interest	\$ 49,743	\$ 30,946	\$
	=====	=====	=====

Edgar Filing: DIACRIN INC /DE/ - Form 10-K

The accompanying notes are an integral part of these financial statements.

F-5

Diacrin, Inc.

Notes to Financial Statements

(1) Operations and Basis of Presentation

Diacrin, Inc. (the "Company") was incorporated on October 10, 1989 and is developing cell transplantation technology for the treatment of human diseases that are characterized by cell dysfunction or cell death and for which current therapies are either inadequate or nonexistent.

(2) Summary of Significant Accounting Policies

(a) Depreciation and Amortization

The Company provides for depreciation using the straight-line method by charges to operations in amounts estimated to allocate the cost of these assets over a five-year life. Amortization of leasehold improvements is computed using the straight-line method over the shorter of the estimated useful life of the asset or the lease term.

(b) Research and Development

Collaborative revenue under the joint venture agreement with Genzyme Corporation ("Genzyme") (see Note 4) and revenues from research grants are recognized as work is performed. Collaborative revenue under the joint venture agreement is recognized as revenue to the extent that the Company's research and development costs are funded by Genzyme through the joint venture. The Company receives non-refundable monthly advances from the joint venture. Deferred revenue represents amounts received prior to recognition of revenue. Research and development costs are expensed as incurred.

(c) Income Taxes

The Company accounts for income taxes in accordance with Statement of Financial Accounting Standards ("SFAS") No. 109, Accounting for Income Taxes. At December 31, 2001, the Company has a net operating loss carryforward for federal income tax purposes of approximately \$53,400,000. The difference from losses reported for financial reporting purposes relates primarily to expenses reflected in the financial statements not yet deductible for tax purposes. The net operating loss carryforwards expire commencing in the year 2006 and are subject to review and possible adjustment by the Internal Revenue Service. Net operating loss and tax credit carryforwards may be limited in the event of certain changes in the ownership interests of significant shareholders. The Company believes the issuance of the convertible notes payable in May 1995, as well as the initial public offering in February 1996, caused a change in ownership, as defined by the Tax Reform Act of 1986 (the "Act"). Additionally, the Company's private placement in 1998 and secondary offering in 2000 may cause a

Diacrin, Inc.

Notes to Financial Statements - (Continued)

change in ownership, as defined by the Act. The Company does not believe that such ownership changes will significantly impact the Company's ability to utilize the net operating loss and tax credit carryforwards as of the date of such ownership changes. Ownership changes in future periods may limit the Company's ability to utilize net operating loss and tax credit carryforwards.

The components of the net deferred tax assets are approximately as follows:

	2000	2001
	----	----
Loss carryforwards	\$19,900,000	\$21,360,000
Credit carryforwards	4,900,000	4,250,000
Other temporary differences	13,500	43,500
	-----	-----
Total deferred tax assets	24,813,500	25,653,500
Less - valuation allowance	(24,813,500)	(25,653,500)
	-----	-----
Net deferred tax asset	\$ -	\$ -
	=====	=====

A valuation allowance has been provided as it is uncertain if the Company will realize the deferred tax assets. The change in the total valuation allowance during the year ended December 31, 2001 was an increase of approximately \$840,000 and relates to the increase in the deferred tax asset which is primarily due to the net operating loss generated during 2001.

(d) Net Loss per Common Share

In accordance with SFAS No. 128, Earnings per Share, basic and diluted net loss per share is calculated by dividing the net loss by the weighted average number of common shares outstanding for all periods presented. Diluted weighted average shares outstanding for all periods presented exclude the potential common shares from stock options and warrants of 4,111,523, 1,258,247 and 1,263,872 at December 31, 1999, 2000, and 2001, respectively, because to include such shares would have been antidilutive.

(e) Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.

Edgar Filing: DIACRIN INC /DE/ - Form 10-K

Diacrin, Inc.

Notes to Financial Statements - (Continued)

(f) Comprehensive Income

In June 1997, the Financial Accounting Standards Board ("FASB") issued SFAS No. 130, Reporting Comprehensive Income ("SFAS 130"). SFAS 130 establishes standards for reporting and display of comprehensive income and its components (revenues, expenses, gains and losses) in a full set of general-purpose financial statements. This statement is effective for fiscal years beginning after December 15, 1997. The Company adopted this statement for the year ended December 31, 1998 with no impact on the Company's financial statements as there are no differences between the Company's reported income and comprehensive income for all periods presented.

(g) Segment Reporting

In June 1997, the FASB issued SFAS No. 131, Disclosure about Segments of an Enterprise and Related Information ("SFAS 131"). SFAS 131 establishes standards for the way that public business enterprises report information about operating segments in annual financial statements and requires that enterprises report selected information about operating segments in interim financial reports issued to stockholders. The Company adopted this statement for the year ended December 31, 1998. In accordance with SFAS 131, the Company believes that it operates in one operating segment.

(h) Fair Value of Financial Instruments

Financial instruments consist mainly of cash and cash equivalents, short-term investments, long-term investments, accounts payable, current portion of long-term debt and long-term debt. The carrying amounts of these instruments approximate their fair value.

(i) New Accounting Standards

In August 2001, the FASB issued SFAS No. 144, Accounting for the Impairment or Disposal of Long-Lived Assets. This Statement supersedes SFAS No. 121, Accounting for the Impairment of Long-Lived Assets and for Long-Lived Assets to Be Disposed Of, and portions of Accounting Principles Bulletin Opinion 30, Reporting the Results of Operations. This Statement provides a single accounting model for long-lived assets to be disposed of and significantly changes the criteria that would have to be met to classify an asset as held-for-sale. In addition, it requires expected future operating losses from discontinued operations to be displayed in the period(s) in which the losses are incurred, rather than as of the measurement date as presently required. This Statement is effective for fiscal years beginning after December 15, 2001. The Company does not expect adoption of this Statement to have a material impact on the Company's financial statements.

F-8

Diacrin, Inc.

Notes to Financial Statements - (Continued)

Edgar Filing: DIACRIN INC /DE/ - Form 10-K

(3) Sale of Common Stock

In March 2000, the Company completed a public offering of 3,450,000 shares of its common stock for \$11.50 per share for net proceeds of approximately \$36.9 million.

(4) Joint Venture Agreement

In September 1996, the Company and Genzyme Corporation formed a joint venture to develop and commercialize the Company's NeuroCell-PD and NeuroCell-HD products for transplantation into people with advanced Parkinson's disease and Huntington's disease, respectively. Under the terms of the joint venture agreement, which was effective October 1, 1996, Genzyme agreed to provide 100% of the first \$10 million in funding and 75% of the following \$40 million in funding for the two products. All costs incurred in excess of \$50 million will be shared equally between Genzyme and the Company in accordance with the terms of the agreement. Any profits of the joint venture will be shared equally by the two parties. As of December 31, 2001, Genzyme had provided \$33.0 million to the joint venture and the Company had provided \$7.6 million.

The Company records as research and development expense all costs related to NeuroCell-PD and NeuroCell-HD incurred by it on behalf of the joint venture. The Company recognizes research and development revenue equal to the amount of reimbursement received by it from the joint venture out of funds contributed by Genzyme. The Company does not recognize research and development revenue for amounts received from the joint venture out of funds it contributed. As Genzyme incurs costs on behalf of the joint venture that the Company is obligated to fund, it recognizes an expense in its statement of operations captioned "Equity in operations of joint venture."

F-9

Diacrin, Inc.

Notes to Financial Statements - (Continued)

Genzyme agreed to make financing available to Diacrin from and after the date that Genzyme provides the initial \$10 million of funding to the joint venture. Genzyme agreed to make available to Diacrin an unsecured, subordinated line of credit of up to an aggregate amount of \$10 million. Diacrin may draw on the line only in the event that Diacrin's cash and cash equivalents are insufficient to fund Diacrin's budgeted operations for a specified period of time, and the funds may be used by Diacrin only to fund capital contributions to the joint venture. The line will be available through the date five years after the date Diacrin first draws on the line, and all outstanding principal and interest will be due on that fifth anniversary. Advances will be interest-bearing, evidenced by a promissory note and subject to other considerations and the aggregate amount of draws in any calendar year may not exceed \$5 million. Diacrin did not make any draws on the line through December 31, 2001.

The Company accounts for its investment in the joint venture on the equity method. The detail of the Company's investment in the joint venture is as follows:

Edgar Filing: DIACRIN INC /DE/ - Form 10-K

	1999	2000	2001
	----	----	----
Balance, beginning of year	\$ 94,508	\$103,730	\$ 4,785
Contributions to joint venture	2,669,384	1,947,422	1,086,545
Return of capital	(990,282)	(693,932)	(245,589)
Funding of operations of joint venture	(1,669,880)	(1,352,435)	(761,757)
	-----	-----	-----
Balance, end of year	\$103,730	\$4,785	\$83,984
	=====	=====	=====

Contributions to the joint venture represent cash contributions. The return of capital represents cash payments made to the Company by the joint venture for research and development costs that are funded by the Company. Funding of operations of the joint venture represents costs incurred by Genzyme on behalf of the joint venture, which are funded by the Company.

A summary of the revenue and expenses from the joint venture are as follows:

	1999	2000	2001
	----	----	----
Revenue recognized (see note 2b)	\$2,970,846	\$2,081,795	\$737,290
Research and development expense (see note 2b)	\$3,961,128	\$2,775,727	\$983,053
Equity in operations of joint venture	\$1,688,071	\$1,368,945	\$546,562

Genzyme's President and Chief Executive Officer is a director of the Company.

F-10

Diacrin, Inc.

Notes to Financial Statements - (Continued)

(5) Cash, Cash Equivalents and Investments

The Company's cash equivalents and investments are classified as held-to-maturity and are carried at amortized cost, which approximates market value. Cash equivalents, short-term investments and long-term investments have maturities of less than three months, less than one year and greater than one year, respectively. Cash and cash equivalents, short-term investments and long-term investments at December 31, 2000 and 2001 consisted of the following:

2000

Edgar Filing: DIACRIN INC /DE/ - Form 10-K

Cash and cash equivalents-	
Cash	\$ 806
Corporate note	1,006,519
Money market mutual fund	10,135,791

	\$11,143,116
	=====
Short-term investments-	
Corporate notes (remaining avg. maturity of 5 mos. at Dec. 31, 2001)	\$22,485,675
US Gov't Obligations (remaining avg. maturity of 8 mos. at Dec. 31, 2001)	-
Commercial paper (remaining avg. maturity of 2 mos. at Dec. 31, 2001)	-

	\$22,485,675
	=====
Long-term investments-	
Corporate notes (remaining avg. maturity of 16 mos. at Dec. 31, 2001)	\$20,977,940
US Gov't Obligations (remaining avg. maturity of 13 mos. at Dec. 31, 2001)	-

	\$20,977,940
	=====

During the year ended December 31, 2001 the Company sold two of its held-to-maturity investments due to significant evidence of deterioration in the issuers' creditworthiness. The cost of the two investments was approximately \$5.5 million and the sale resulted in a realized gain of approximately \$96,000, which is included in Investment Income on the statement of operations for the current period. This sale represents a change in circumstances as defined in SFAS No. 115 Accounting for Certain Investments in Debt and Equity Securities and does not taint the remaining portfolio of the Company's held-to-maturity investments as the Company continues with the intent and ability to hold its investments to maturity.

F-11

Diacrin, Inc.

Notes to Financial Statements - (Continued)

(6) Accrued Expenses

Accrued expenses consisted of the following at December 31, 2000 and 2001:

	2000	2001
	----	----
Accrued clinical trials costs	\$ 812,384	\$ 499,341
Accrued professional fees	159,999	138,364
Accrued payroll	114,899	288,813
Accrued contract research costs	54,862	98,934
Accrued other	181,642	243,826
	-----	-----
Total	\$1,323,786	\$1,269,278
	=====	=====

Edgar Filing: DIACRIN INC /DE/ - Form 10-K

(7) Long-term Debt

In November 1997, the Company entered into an unsecured term loan agreement with a bank whereby the bank loaned the Company \$650,000 to construct a pilot manufacturing facility. Interest accrues at the prime rate plus one-half of one percent (5.25% at December 31, 2001) and is payable monthly in arrears. The loan is payable in 60 principal installments of \$10,833 commencing December 1, 1997 and may be prepaid without penalty. The Company is required to maintain certain covenants, including certain financial ratios and unencumbered cash balances of not less than \$1 million. As of December 31, 2001, the Company was in compliance with all covenants. Principal payments on the loan for the next year will be \$119,167.

(8) Preferred Stock

The Company has authorized 5,000,000 shares of undesignated preferred stock. The Company's Board of Directors is authorized, subject to any limitations prescribed by law and without further stockholder approval, to issue from time to time up to 5,000,000 shares of preferred stock in one or more series. Each such series of preferred stock shall have such number of shares, designations, preferences, voting powers, qualifications and rights or privileges as shall be determined by the Board of Directors.

(9) Common Stock Options

The Company has adopted the 1990 Stock Option Plan (the "1990 Plan") under which the Board of Directors is authorized to grant incentive stock options, non-qualified stock options and stock appreciation rights to employees, directors and consultants of the Company for up to 800,000 shares of the Company's common stock. All options granted have 10-year terms, and the majority vest in equal annual installments of 25% over four years of continued service from the date of hire or grant. As of December 31, 2001, there were options to purchase 99,045 shares of common stock available for future grant under the 1990 Plan.

F-12

Diacrin, Inc.

Notes to Financial Statements - (Continued)

In July 1994, the stockholders approved the 1994 Directors' Stock Option Plan (the "Director Plan") which automatically grants an option to each eligible outside director of the Company for the purchase of 7,500 shares of common stock at an exercise price of the then fair market value. Each option granted under the Director Plan has a 10-year term and may be exercised on a cumulative basis as to 25% of the shares on the first anniversary of the date of grant and an additional 25% at the end of each one-year period thereafter. In December 1996, the Board of Directors amended the Director Plan to automatically grant 15,000 options to each new eligible outside director. The Company has reserved 30,000 shares for issuance under this plan. As of December 31, 2001, there were 15,000 options outstanding under the Director Plan at a weighted average exercise price of \$9.50 per share. As of December 31, 2001, there were options to purchase 13,125 shares of common stock available for future grant under the Director Plan.

In June 1997, the stockholders approved the 1997 Stock Option Plan (the

Edgar Filing: DIACRIN INC /DE/ - Form 10-K

"1997 Plan") under which the Board of Directors is authorized to grant incentive stock options and non-qualified stock options to employees, directors and consultants of the Company for up to 1,200,000 shares of the Company's common stock. All options granted have 10-year terms, and vest in equal annual installments of 25% over four years of continued service from the date of hire or grant. As of December 31, 2001, options to purchase 572,375 shares of common stock were available for future grant under the 1997 Plan.

F-13

Diacrin, Inc.

Notes to Financial Statements - (Continued)

The following table summarizes incentive and non-qualified stock option activity:

	Number of options	Weighted average Exercise price
Balance, December 31, 1998	1,125,738	\$ 4.87
Options granted	183,500	5.97
Options exercised	(58,965)	1.02
Options canceled	(13,750)	11.20
	-----	-----
Balance, December 31, 1999	1,236,523	5.14
Options granted	154,750	5.56
Options exercised	(75,526)	2.66
Options canceled	(57,500)	8.91
	-----	----
Balance, December 31, 2000	1,258,247	5.15
Options granted	32,000	2.18
Options exercised	(22,500)	1.25
Options canceled	(3,875)	6.27
	-----	----
Balance, December 31, 2001	1,263,872	\$ 5.14
	=====	=====
Exercisable, December 31, 2001	988,996	\$ 5.08
	=====	=====
Exercisable, December 31, 2000	860,869	\$ 4.68
	=====	=====
Exercisable, December 31, 1999	822,332	\$ 4.15
	=====	=====

All options have been granted at the fair market value of the Company's common stock on the date of grant.

F-14

Diacrin, Inc.

Edgar Filing: DIACRIN INC /DE/ - Form 10-K

Notes to Financial Statements - (Continued)

The following table summarizes certain information about options outstanding and exercisable at December 31, 2001:

Options outstanding			
Range of exercise prices	Number of exercisable at December 31, 2001	Weighted average remaining contractual life	Weighed average exercise price
\$1.22 to \$2.50	528,497	2.74	\$2.11
\$4.50 to \$7.50	470,750	7.67	\$5.74
\$7.88 to \$15.75	264,625	5.81	\$10.12
	1,263,872		\$5.14
	=====		=====

Options exercisable		
Range of exercise prices	Number exercisable At December 31, 2001	Weighted average exercise price
\$1.22 to \$2.50	498,497	\$2.12
\$4.50 to \$7.50	250,562	\$5.97
\$7.88 to \$15.75	239,937	\$10.31
	988,996	\$5.08
	=====	=====

The Company has adopted SFAS No. 123, Accounting for Stock-Based Compensation. As permitted by SFAS No. 123, the Company has continued to account for employee stock options in accordance with Accounting Principles Board Opinion No. 25, Accounting for Stock Issued to Employees, and has included the proforma disclosure required by SFAS No. 123 for all periods presented.

Pro forma information regarding net income (loss) and earnings (loss) per share is required by SFAS No. 123, and has been determined as if the Company had accounted for its employee and director stock options under the fair value method of SFAS No. 123. The fair-value for these options was estimated at the date of grant using a Black-Scholes option pricing model with the following assumptions for 1999, 2000 and 2001: risk-free interest rates of 6.0% for all years; dividend yield of 0% for all years; volatility factor of the expected market price of the Company's common stock of 95% for all years; and a weighted-average expected life of the options of 7.5 years for all years. The weighted average fair value of options granted in 1999, 2000 and 2001 was \$4.97, \$4.71 and \$1.85, respectively.

Edgar Filing: DIACRIN INC /DE/ - Form 10-K

Notes to Financial Statements - (Continued)

For purposes of pro forma disclosure, the estimated fair value of the options is amortized to expense over the options' vesting period. The aggregate fair value of options granted in 1999, 2000 and 2001 was approximately \$912,000, \$729,000 and \$59,082, respectively. The Company's pro forma information follows:

		1999 ----	2000 ----	2001 ----
Net loss	As reported	\$(4,760,315)	\$(3,536,741)	\$(4,648,250)
	Pro forma	\$(5,796,810)	\$(4,714,923)	\$(5,612,794)
Basic and diluted net loss per share:	As reported	\$ (.33)	\$ (.21)	\$ (.26)
	Pro forma	\$ (.40)	\$ (.27)	\$ (.31)

(10) Facility Lease

During 1991, the Company entered into a 10-year operating lease for a facility. In October 2000, the Company exercised the first of two options to extend the lease an additional five years commencing October 2001. Minimum rental payments under the lease are as follows:

	Rental Commitment -----
2002	\$ 898,000
2003	898,000
2004	898,000
2005	898,000
2006	673,000

	\$ 4,265,000
	=====

Total rent expense for the years ended December 31, 1999, 2000 and 2001 was approximately \$761,000, \$751,000 and \$758,000, respectively.

(11) Employment Retirement / Savings Plan

The Company maintains an employee retirement / savings plan (the "Plan") which permits participants to make tax deferred contributions by salary reduction pursuant to section 401(k) of the Internal Revenue Code. All active employees, 21 years of age or older, who have completed a calendar quarter of service are eligible to participate in the Plan. The Company pays all administrative costs of the Plan. There were no contributions made to the Plan by the Company in 1999. During 2000 and 2001, the Company made discretionary contributions of \$28,500 and \$54,700, respectively, to the Plan.

Edgar Filing: DIACRIN INC /DE/ - Form 10-K

Notes to Financial Statements - (Continued)

(12) Quarterly Results of Operations (Unaudited)

The following table presents a condensed summary of quarterly results of operations for the years ended December 31, 2001 and 2000.

	Year Ended December 31, 2001			
	First Quarter -----	Second Quarter -----	Third Quarter -----	Fourth Quarter -----
Total revenue	\$ 1,292 =====	\$ 990 =====	\$ 909 =====	\$ 696 =====
Net loss	\$ (811) =====	\$ (1,334) =====	\$ (1,175) =====	\$ (1,328) =====
Basic and diluted net loss per common share	\$ (.05) =====	\$ (.07) =====	\$ (.07) =====	\$ (.07) =====
	Year Ended December 31, 2000			
	First Quarter -----	Second Quarter -----	Third Quarter -----	Fourth Quarter -----
Total revenue	\$ 863 =====	\$ 1,404 =====	\$ 1,543 =====	\$1,397 =====
Net loss	\$ (1,249) =====	\$ (808) =====	\$ (820) =====	\$ (660) =====
Basic and diluted net loss per common share	\$ (.09) =====	\$ (.05) =====	\$ (.05) =====	\$ (.04) =====

F-17

Report of Independent Accountants

To the Steering Committee of Diacrin/Genzyme LLC:

In our opinion, the accompanying balance sheet and the related statement of operations, of cash flows and of changes in Venturers' capital (deficit) present fairly, in all material respects, the financial position of Diacrin/Genzyme LLC (a development stage enterprise) at December 31, 2000, and the results of its operations and its cash flows for the period then ended (information for the period ended December 31, 2001 and from inception through December 31, 2001 is unaudited), in conformity with accounting principles generally accepted in the United States of America. These financial statements are the responsibility of the Steering Committee of the Joint Venture; our responsibility is to express an opinion on these financial statements based on our audit. We conducted our

Edgar Filing: DIACRIN INC /DE/ - Form 10-K

audit of these statements in accordance with auditing standards generally accepted in the United States of America, which require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, and evaluating the overall financial statement presentation. We believe that our audit provides a reasonable basis for our opinion.

As more fully discussed in Note A, either Venturer may terminate the Collaboration Agreement of the Joint Venture for any reason upon 180 days notice to the other Venturer and such termination could lead to the discontinuation of the Joint Venture.

/s/ PricewaterhouseCoopers LLP

Boston, Massachusetts
January 26, 2001

F-18

Diacrin/Genzyme LLC (A Development Stage Enterprise)

Balance Sheets December 31, 2000 and 2001

	2000	2001 (Unaudited)
Assets		
Current assets:		
Cash	\$ 1,032,170	\$ 498,093
Prepaid to Diacrin, Inc. (Note C)	365,245	50,014
Other current assets	11,266	11,267
	-----	-----
Total current assets	1,408,681	559,374
Property and equipment, net (Note D)	156,176	106,365
	-----	-----
Total assets	\$ 1,564,857	\$ 665,739
	=====	=====
Liabilities and Venturers' Capital (Deficit)		
Payable to Genzyme Corporation (Note C)	\$ 2,150,488	\$ 77,699
Accrued expenses	23,900	-
	-----	-----
Total liabilities	2,174,388	77,699
Commitments and contingencies (Note C)		

Edgar Filing: DIACRIN INC /DE/ - Form 10-K

Venturers' capital (deficit) (including deficit accumulated during the development stage of \$40,041,520);

Venturers' capital - Genzyme Corporation	444,140	485,654
Venturers' capital - Diacrin, Inc.	88,548	102,386
Unpaid Venturers' capital - Genzyme Corporation	(861,664)	-
Unpaid Venturers' capital - Diacrin, Inc.	(280,555)	-
	-----	-----
Total Venturers' capital (deficit)	(609,531)	588,040
	-----	-----
Total liabilities and Venturers' capital (deficit)	\$ 1,564,857	\$ 665,739
	=====	=====

The accompanying notes are an integral part of these financial statements.

F-19

Diacrin/Genzyme LLC
(A Development Stage Enterprise)

Statements of Operations

	2000	2001 (Unaudited)	For the fr October (date of i to Dece 2 (Unau
Operating costs and expenses:			
Research and development - Genzyme Corporation	\$ 5,394,335	\$ 2,178,191	\$ 21,
Research and development - Diacrin, Inc.	2,736,293	983,054	18,
General and administrative	90,113	64,959	
	-----	-----	-----
Total operating costs and expenses	8,220,741	3,226,204	40,
Interest income	8,667	56,902	
	-----	-----	-----
Net loss	\$ (8,212,074)	\$ (3,169,302)	\$ (40,
	=====	=====	=====

The accompanying notes are an integral part of these financial statements.

F-20

Diacrin/Genzyme LLC
(A Development Stage Enterprise)

Statements of Cash Flows

	2000	2001 (Unaudited)	For Oct (date to (
Cash flows from operating activities:			
Net loss	\$ (8,212,074)	\$ (3,169,302)	\$ (4
Reconciliation of net loss to net cash used			
Depreciation	49,146	49,811	
Increase (decrease) in cash from working			
Prepaid to Diacrin, Inc.	68,467	315,230	
Payable to Genzyme Corporation	1,202,400	(2,072,790)	
Other current assets	(11,266)	-	
Accrued expenses	(453)	(23,900)	
	-----	-----	
Net cash used by operating activities	(6,903,780)	(4,900,951)	(3
Cash flows from investing activities:			
Acquisition of property and equipment	(13,268)	-	
Cash flows from financing activities:			
Capital contributed by Genzyme Corporation	5,992,265	3,280,155	3
Capital contributed by Diacrin, Inc.	1,947,422	1,086,719	
	-----	-----	

Edgar Filing: DIACRIN INC /DE/ - Form 10-K

Net cash provided by financing activities	7,939,687	4,366,874
	-----	-----
Increase (decrease) in cash	1,022,639	(534,077)
Cash at beginning of period	9,531	1,032,170
	-----	-----
Cash at end of period	\$ 1,032,170	\$ 498,093
	=====	=====

The accompanying notes are an integral part of these financial statements.

F-21

Diacrin/Genzyme LLC
(A Development Stage Enterprise)

Statements of Changes in Venturers' Capital (Deficit)
For the Period from October 1, 1996 (Date of Inception) to December 31, 2001

	Genzyme Corporation	Diacrin, Inc.	Unpaid Venturers Genzyme Corporation
1996 capital contributions	\$ 1,911,968	\$ -	\$ -
1996 net loss	(1,542,374)	-	-
	-----	-----	-----
Balance at December 31, 1996	369,594	-	-
1997 capital contributions	6,819,536	-	-
1997 net loss	(6,809,012)	-	-
	-----	-----	-----
Balance at December 31, 1997	380,118	-	-
1998 capital contributions	7,709,137	2,085,079	(704,415)
1998 net loss	(7,608,663)	(1,986,683)	-
	-----	-----	-----
Balance at December 31, 1998	480,592	98,396	(704,415)
1999 capital contributions	8,068,415	2,691,774	(60,267)
1999 net loss	(8,035,058)	(2,678,353)	-

Edgar Filing: DIACRIN INC /DE/ - Form 10-K

Balance at December 31, 1999	513,949	111,817	(764,682)
2000 capital contributions	6,089,247	2,029,749	(96,982)
2000 net loss	(6,159,056)	(2,053,018)	-
Balance at December 31, 2000	444,140	88,548	(861,664)
2001 capital contributions (Unaudited)	2,418,491	806,164	861,664
2001 net loss (Unaudited)	(2,376,977)	(792,326)	-
Balance at December 31, 2001 (Unaudited)	\$ 485,654	\$ 102,386	\$ -

The accompanying notes are an integral part of these financial statements.

F-22

Diacrin/Genzyme LLC
(A Development Stage Enterprise)

Notes to December 31, 2001 Financial Statements
(Information for the period ended December 31, 2001 and from inception through December 31, 2001 is unaudited)

A. Nature of Business and Organization

On October 1, 1996, Diacrin/Genzyme LLC ("the Joint Venture") was established as a joint venture between Genzyme Corporation ("Genzyme") and Diacrin, Inc. ("Diacrin") (collectively, the "Venturers"), to develop and commercialize products and processes for use in the treatment of Parkinson's disease and Huntington's disease in humans using porcine fetal cells. Under the terms of the Collaboration Agreement among Diacrin, Genzyme and the Joint Venture (the "Collaboration Agreement"), all funding is provided by the Venturers, and all payments for work performed are made to the Venturers. Genzyme provided the initial \$10.0 million of the funding requirements, and the next \$40.0 million of the funding requirements are to be provided 75% by Genzyme and 25% by Diacrin. After \$50.0 million has been funded, any additional funding will be provided equally by the Venturers. Funding is provided on a monthly basis. Profits and losses from the Joint Venture will be shared in proportion to the then current capital contribution ratio of each Venturer. The Joint Venture reimburses the Venturers for costs incurred based upon the dollar amount of work, at a defined cost, that each Venturer performs on behalf of the Joint Venture. All general and administrative expenses recorded on the statements of operations are for costs incurred by and reimbursed to the Venturers. See also

Edgar Filing: DIACRIN INC /DE/ - Form 10-K

Note C.

The Steering Committee of the Joint Venture is comprised of representatives of each Venturer. The Steering Committee is responsible for approving the budget of the Joint Venture, reviewing costs incurred by the Venturers and monitoring the scientific progress of the Joint Venture.

The Joint Venture is subject to risks common to companies in the biotechnology industry, including but not limited to, the results of clinical trials development by its competitors of new technological innovations, protection of proprietary technology, health care cost containment initiatives, product liability and compliance with government regulations, including those of the United States Department of Health and Human Services and the United States Food and Drug Administration.

In addition, either Venturer may terminate the Collaboration Agreement for any reason upon 180 days notice to the other Venturer. During the 180-day period, the obligations of the Venturers, including without limitation obligations with respect to capital contributions, will continue in full force and effect. A decision by one or both of the Venturers to discontinue the Collaboration Agreement for any reason could lead to the discontinuation of the Joint Venture.

F-23

Diacrin/Genzyme LLC
(A Development Stage Enterprise)

Notes to December 31, 2001 Financial Statements - (Continued)
(Information for the period ended December 31, 2001 and
from inception through December 31, 2001 is unaudited)

The intangible assets and technological know-how contributed by Diacrin to the Joint Venture are not included as an asset in these financial statements, because generally accepted accounting principles require that the Joint Venture record contributed assets at the book value of the Venturer, at the time of the asset transfer the book value was \$0.

B. Summary of Significant Accounting Policies

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reported period. Actual results could differ from those estimates.

Cash and Cash Equivalents

Cash and cash equivalents, consisting principally of money market funds and municipal notes purchased with initial maturities of three months or less, are valued at cost plus accrued interest, which approximates market.

Property and Equipment

Depreciation expense is computed on a straight-line basis over the useful life of the property and equipment (3 to 10 years), and over the lesser of the life of the lease or the life of the leasehold improvement. When assets are retired or otherwise disposed of, the assets and the related accumulated

Edgar Filing: DIACRIN INC /DE/ - Form 10-K

depreciation are removed from the accounts and any resulting gains or losses are included in the results of operations.

Research and Development Expenses

Research and development costs are expensed as incurred. The research and development efforts are being conducted by the Venturers. The costs incurred by these related parties, which are subject to an annual budget approved by the Joint Venture's Steering Committee, are then charged to the Joint Venture, at a defined cost, or at amounts agreed to by the Venturers.

Income Taxes

The Joint Venture is organized as a pass-through entity; accordingly, the financial statements do not include a provision for income taxes. Taxes, if any, are the liability of Genzyme and Diacrin, as Venturers.

F-24

Diacrin/Genzyme LLC (A Development Stage Enterprise)

Notes to December 31, 2001 Financial Statements - (Continued)
(Information for the period ended December 31, 2001 and
from inception through December 31, 2001 is unaudited)

C. Agreements with Venturers

Funding

Genzyme agreed to make available to Diacrin an unsecured, subordinated line of credit (the "Line") of up to an aggregate amount of \$10.0 million after the date that Genzyme provided the initial \$10.0 million of funding to the Joint Venture. Diacrin may draw on the Line only in the event that Diacrin's cash and cash equivalents are insufficient to fund Diacrin's budgeted operations for a specified period of time, and the funds may be used by Diacrin only to fund capital contributions to the Joint Venture. The Line will be available through the date five years after the date Diacrin first draws on the Line, and all outstanding principal and interest will be due on that fifth anniversary. Advances will be interest bearing, evidenced by a promissory note and subject to other considerations; and the aggregate amount of draws in any calendar year may not exceed \$5.0 million. As of December 31, 2001, Diacrin had not made any draws on the Line.

During the year ended December 31, 1998, Genzyme provided its initial \$10.0 million of funding to the Joint Venture. After the initial \$10.0 million, Genzyme and Diacrin provide 75% and 25%, respectively, of the next \$40.0 million of funding to the Joint Venture. Thereafter, all funding will be shared equally by the two parties. As of December 31, 2001, Genzyme and Diacrin have funded \$33.0 million and \$7.6 million, respectively.

Other Agreements

The payable to Genzyme Corporation will be settled by cash payment and represents costs incurred by Genzyme that are reimbursable under the Collaboration Agreement. The prepaid to Diacrin is an estimate of the reimbursable costs Diacrin expects to incur on behalf of the Joint Venture in the next month.

At December 31, 2000, both Venturers had funded less than their allocated losses which resulted in unpaid Venturer's capital and represents receivables from the Venturers.

Edgar Filing: DIACRIN INC /DE/ - Form 10-K

Genzyme charges the Joint Venture for use of certain research and development facilities under a three-year agreement which commenced July 1, 1998. The charges were \$364,164 for the year ended December 31, 2000. The charges were \$182,082 and \$1,520,802 for the year ended December 31, 2001 and period from inception through December 31, 2001 (unaudited).

F-25

Diacrin/Genzyme LLC
(A Development Stage Enterprise)

Notes to December 31, 2001 Financial Statements - (Continued)
(Information for the period ended December 31, 2001 and
from inception through December 31, 2001 is unaudited)

D. Property and Equipment

Property and equipment is stated at cost. At December 31, 2000 and 2001, property and equipment consisted of the following:

	2000	2001
Lab equipment	\$200,199	\$200,199
Computer equipment	71,991	71,991
Leasehold improvements	27,608	27,608
Furniture and fixtures	12,963	12,963
	-----	-----
	312,761	312,761
Less: accumulated depreciation	(156,585)	(206,396)
	-----	-----
Property and equipment, net	\$156,176	\$106,365
	=====	=====

Depreciation expense was \$49,146 and \$49,811 for the years ended December 31, 2000 and 2001 (unaudited), respectively, and \$206,396 from inception through December 31, 2001 (unaudited).

F-26